丹蒲胶囊对自身免疫性前列腺炎模型相关细胞因子的调节机制研究及临床观察
|
摘要
慢性前列腺炎(Chronic Prostatitis,CP)是中青年男性的常见病、多发病,该病症状复杂,病程较长,且容易复发,严重影响患者的身心健康。如何提高临床疗效,改善患者临床症状,是目前该研究领域中最迫切的课题。
导师张亚强教授是中西医结合泌尿外科专家刘猷枋教授的学术继承人,他在充分继承刘猷枋教授学术经验的基础上,在运用活血化瘀法治疗慢性前列腺炎方面有其独到之处。本论文在对中医治疗慢性前列腺炎历代文献整理基础上,对导师治疗慢性前列腺炎的临床经验,用现代科学手段进行了深入挖掘。同时,以自身免疫性前列腺炎大鼠模型为载体,采用酶联接免疫吸附测定法(ELISA)、实时荧光定量PCR(RT-PCR)等技术,从整体——细胞因子——基因等层次,深入探讨了活血化瘀法及组方丹蒲胶囊治疗慢性前列腺炎的分子机制,从一个侧面揭示了中医药治疗慢性前列腺炎的理论依据和导师临床治验的科学内涵。
一、理论研究
1.历代医家著述对后世慢性前列腺炎的治疗具有指导意义
通过整理祖国医学历代文献对慢性前列腺炎的认识,可以总结出中医对该病的认识可分为四个时期:①秦汉时期为萌芽期,对前列腺炎形成了初步的认识;②隋唐时期是发展期,在原有认识基础上又有了一定的发展,该时期医家对淋证病因病机、治法、方药有了更深一步的描述,尤其是淋证分类出现了七淋、五淋的见解,为以后的发展奠定了坚实的基础;③宋金元时期是充实期,这一时期百家争鸣,产生了很多学术流派,派生出许多学术观点,对“淋、浊、小便不利”的见解更深刻、特点更鲜明;④明清时期是成熟期,是这一疾病的集大成期。明清医家在充分继承前贤学术思想的同时,又结合自己的临床体验,不断地推陈出新,使对“淋”、“浊”、“小便不利”等的认识更加成熟,更加趋于完善。
如何充分挖掘祖国医学文献这一宝库,并以此为切入点,探讨现代中医对慢性前列腺炎辨证论治规律并指导临床,将对当代慢性前列腺炎的中医治疗学的发展产生深远的意义。
2.导师治疗慢性前列腺炎的学术经验
导师在充分继承了刘猷枋教授学术思想的基础上,根据“血瘀贯穿疾病发展始终”的病机特点,临床治疗:①将活血化瘀法作为治疗该病的根本方法,在活血基础上,根据疾病的寒热虚实辨证论治,兼湿热者,佐以清热利湿;兼肾虚者,辅以补肾中药;②根据病程、病情程度论治,轻证多以湿热、血瘀者为多,治以清热利湿、活血止痛;重证或顽固证病程日久,多虚多瘀,在活血益气的基础上,重用三棱、莪术、王不留行、穿山甲等破血化瘀药,同时佐以虫类物如水蛭、地龙等;③注重心理疏导,强调饮食调摄。大量的临床实践表明,长期坚持活血化瘀法中医药治疗能改善患者临床症状(尤其对疼痛的缓解尤为突出),提高患者的生活质量。
二、临床研究
1.借助数据挖掘方法,总结导师治疗慢性前列腺炎的学术经验
利用数据挖掘生物信息学技术,以导师临床诊疗典型病例为研究对象,以保留导师辨证论治特色的结构化的临床数据为基础,以方药为线索,利用频数分析,从多个角度进行分析对比、综合归纳,初步研究名老中医的方——证关系、证——药、症——药关系等,提取导师辨证特点和遣方用药规律等知识,总结导师继承名老专家刘猷枋教授学术思想基础上运用活血化瘀法辨治慢性前列腺炎的学术经验及其理论内涵。
根据90例病历资料分析,展现该病常见临床症状:会阴部不适、尿频、尿不尽、尿后滴白、舌暗红等症状;总结出导师对慢性前列腺炎辨证分为气滞血瘀型、湿热蕴结型、肾虚型3个基本证型,其中,临床两证、三证兼见时有发生。总结出导师治疗慢性前列腺炎常用治法6种、常用药物25味、常用基础方7个、常用的25对药对。在导师常用45味中药功能分类的基础上,归纳出导师在治疗CP的药物使用频次上,活血化瘀药居首位,清热利湿药、补肾药次之,同时采用理气、解表、温里、泻下药等从多方面多层次治疗,说明导师在辨证论治基础上处方,主次分明,脉络清晰。
2丹蒲胶囊治疗慢性前列腺炎的临床研究
目的及方法:采用随机对照的方法对丹蒲胶囊治疗慢性前列腺炎进行再评价。
结论:①丹蒲胶囊治疗慢性前列腺炎的总有效率为83.3%,对照药前列泰片为56.4%,治疗组优于对照组(P＜0.05)。②丹蒲胶囊能明显降低前列腺液白细胞数(EPS-WBC),增加前列腺液卵磷脂小体密度(EPS-CORP)。治疗后两组EPS-WBC均减少,经统计学处理,两组差异有显著性意义,治疗组优于对照组(P＜0.05);治疗后两组EPS-CORP密度较治疗前均可见增加,经统计学处理,两组差异有显著性意义,治疗组优于对照组(P＜0.05)。③丹蒲胶囊能明显改善少腹疼痛、小便频急、尿后余沥不尽、尿道灼热、会阴疼痛、腰骶部疼痛、睾丸疼痛、阴囊潮湿、尿后滴白等单项症状,降低NIH-CPSI评分、NIH-疼痛评分,提高患者生活质量。其中,在降低EPS-WBC、提高EPS-CORP密度,缓解前列腺炎患者少腹疼痛、小便频急、尿后余沥不尽、尿道灼热等症状,以及降低NIH-CPSI评分、NIH-疼痛评分方面,优于对照组(P＜0.05)。进一步证实了丹蒲胶囊能改善能通过改善慢性前列腺炎患者临床症状(尤其对疼痛症状的缓解)、降低NIH-CPSI评分,而达到其治疗作用,研究展示了中医药治疗慢性前列腺炎的优势。
三、实验研究
本课题实验研究以自身免疫性前列腺炎大鼠模型为载体,采用ELISA、RT-PCR等技术,从整体——细胞因子——基因等层次,深入探讨了活血化瘀法及组方丹蒲胶囊治疗慢性前列腺炎的分子机制,从一个侧面揭示了中医药治疗慢性前列腺炎的理论依据和导师临床治验的科学内涵。
1.优选出建立自身免疫性前列腺炎大鼠模型方法——加强免疫法,为研究丹蒲胶囊治疗慢性前列腺炎的分子机制奠定了坚实的实验基础。
2.应用加强免疫法建立实验性自身免疫性前列腺炎大鼠模型,光镜和电镜下观察丹蒲胶囊对模型组织形态学及超微结构的变化。结果表明:模型组光镜表现:前列腺腺体遭到破坏,间质及腺体充满大量弥散的淋巴细胞、单核细胞;电镜表现:腺体破坏,粗面内质网扩张明显,线粒体扩张或呈空泡化,核膜皱缩,细胞器扩张,染色质周边凝聚。模型组病理改变符合前列腺慢性炎症表现。丹蒲胶囊能明显减轻或消除模型大鼠的前列腺组织炎症,其中,大剂量组最优。为丹蒲胶囊的临床疗效提供了病理组织学依据。
3.丹蒲胶囊对复杂的细胞因子网络有免疫调控作用,对IL-1β、IL-2、IL-8均有抑制作用,对高水平的IL-10有降低效应,同时能抑制NF-κB的表达而发挥治疗作用。
4.丹蒲胶囊对自身免疫性前列腺炎模型大鼠前列腺组织NGF有抑制作用,对前列腺组织及血清中的PGE2水平有降低效应,通过这种抑制作用而发挥该药的镇痛效应。
5.自身免疫性前列腺炎大鼠模型出现NF-κB、NGF基因mRNA的高表达,丹蒲胶囊通过抑制NF-κB、NGF基因mRNA的表达发挥治疗效应。研究从基因水平阐释了中药丹蒲胶囊对慢性前列腺炎治疗作用的分子机制。
四、本研究的特色及创新之处
1.临床研究
在临床应用丹蒲胶囊有效的基础上,利用数据挖掘生物信息学技术,以导师临床诊疗典型病例为研究对象,以保留导师辨证论治特色的结构化临床数据为导向,以方药为线索,利用频数分析,从多个角度进行分析对比、综合归纳,初步研究名老中医的方——证关系、证——药、症——药关系等,提取导师辨证特点和遣方用药规律等知识,总结导师在继承名老专家刘猷枋教授学术思想基础上,运用活血化瘀法辨治慢性前列腺炎的学术经验及理论内涵,为深层次继承挖掘名老专家学术经验提供了新思路。未见同类研究报道。
2.实验研究
2.1优选出成功建立实验性自身免疫性前列腺炎大鼠模型的加强免疫法,为进一步探索前列腺炎的自身免疫学说奠定了实验基础,是本研究的特色之一。
2.2以动物前列腺组织及血清为观察对象,以IL-1β、IL-8、IL-10、IL-2、NF-κB、NGF、PGE2等细胞因子为观测指标,研究了丹蒲胶囊这些因子的调节作用,从一个侧面揭示了丹蒲胶囊免疫调节及镇痛作用的分子机制,为活血化瘀法治疗慢性前列腺炎提供了新的实验依据。在前列腺炎疗效机制的系统研究上未见同类报道。
3.理论创新
本课题针对“前列腺炎与细胞因子”的研究热点,首次提出“活血化瘀法及组方丹蒲胶囊可能通过调控NF-κB、NGF的基因mRNA表达而发挥治疗效应”的假说,应用RT-PCR的方法证实丹蒲胶囊对模型大鼠NF-κB、NGF的基因mRNA的表达有抑制效应,验证了假说。研究揭示了活血化瘀法治疗慢性前列腺炎分子基础的科学内涵,为中医药防治慢性前列腺炎的研究提供了新思路。
Chronic Prostatitis(CP) is a common disease in young and middle aged men.It has impact on physical and mental health with the characteristics of symptom complex,longer course,and easy recurrence.How to improve clinical symptoms and increase the clinical efficacy is the most critical topic in the field of CP currently.
Advisor Professor Zhang Ya-qiang is the academic inheritor of Professor Liu You-fang who is the founder of urology combined traditional Chinese and western medicine in China.On the basis of inheriting academic experience of Professor Liu You-fang,Advisor Professor Zhang often obtain a unique efficacy especially in the treatment of chronic prostatitis by applying the method of promoting blood circulation and removing blood stasis.
According to collecting a great deal of the ancient TCM literature on CP,advisor's clinical experience of treating CP is mined thoroughly by means of modern scientific method.Meanwhile,the experimental autoimmune prostatitis(EAP) animal model was adopted.And the modern techniques of Enzyme-Linked Immunosorbent Assay (ELISA),Real-Time polymerase chain reaction(RT-PCR) were applied to detect test targets.
The molecular mechanisms on DanPu capsule in the therapy of CP were explored at different levels from the whole-cytokine-gene.And the scientific content of the theory of TCM treating CP and the clinical experience of the tutor were revealed from one aspect.
PartⅠ:Theoretical studies
1.The ancient literature of TCM having significant meaning in the therapy of Chronic Prostatitis
On the basis of combing a great deal of the ancient TCM literature about CP,the idea of TCM on such disease was divided into four periods:
①It was the sprouting period that during the Qin & Han Dynasties.
②It was the development period in the Sui and Tang Dynasties.
③It was the substantial period that from the Song Dynasty to Yuan Dynasty.
④It was mature period during the Ming and Qing Dynasties.
2.Academic experience on advisor of treating CP
According to the pathogenesis characteristic of "the syndrome of Blood Stasis is crossing the course of CP",on the basis of inheriting the academic thoughts of Pro LIU You-fang,the clinical experiences of my tutor are as follows:
①To advocate major therapeutic method of promoting blood circulation and removing blood stasis in the therapy of chronic prostatitis.
②To treat CP based on different course and state of patients.
③At the same time,to emphasize the importance of adjusting the food,drink and the mental state.
PartⅡ:Clinical studies
1.The clinical study about medication and syndrome on advisor in thetreatment of Chronic Prostatitis
To make use of the bioinformation data mining(DM),and to take advisor's prescription and medicine as the clues,90 pieces of the primitive prescriptions were carried out to analyze from multi-angles.Regularities were summarized as follow:
①Chronic Prostatitis was divided into three basic syndromes by Syndrome differentiation and treatment.
②6 elementary methods,25 common Chinese herbs,6 elementary prescriptions and 25 couple of herbs were summarized respectively.
③According to functional classification of herbs,it was the first place that a kind of drug for removing blood stasis.It was the second place that a kind of the drug for eliminating dampness and heat and a kind of the drug for nourishing the kidney.
2.the clinical research on DanPu capsule in the therapy of CP
Purpose and method:To reevaluate the clinical efficacy of DanPu capsule treating CP by means of randomized controlled trial(RCT).
Conclusions:①The total effective rate of DanPu capsule and the control drug were 83.3%and 56.4%respectively.The effect in DanPu capsule group is better than that of the control group(P＜0.05).
②DanPu capsule can reduce the white blood count in expressed prostatic secretion(EPS) and increase the lecithin corpuscle count of EPS,which is superior to the control group.
③DanPu capsule can improve clinical symptoms such as pain in the lower abdomen,frequent urination,burning urethra,perineal pain,lumbosacral pain, testicular pain,scrotum humidity and so on.Besides,It can also lower NIH-CPSI (National Institutes of Health Chronic Prostatitis Symptom index),NIH-pain-score and elevate the quality of life.
PartⅢexperimental research
The modern techniques of ELISA and RT-PCR were applied to detect the lab indexes.From the different layers of the whole-cytokine-gene,to explore extremely the molecular mechanisms of DanPu capsule in the therapy of CP.
From one aspect,the scientific content of was brought to light,which were the theories of TCM and the clinical experience of the advisor.
1.Selecting the stable method of establishing experimental autoimmune prostatitis(EAP) animal model—booster immunization.
2.Under light microscope and electron microscope,it is found that DanPu capsule can lessen and eliminate the prostatic inflammation of EAP rat model.
3.DanPu capsule has the inhibitory action on IL-1β,IL-2,IL-8 levels in the prostatic tissue and serum of rats.Meanwhile,it has the descending effect on IL-10 and NF-κB(Nuclear Factor-κB) as well.
4.DanPu capsule has the depressant effect on NGF,PGE2 levels in the prostatic tissue & serum of rats.
5.DanPu capsule has the inhibitory action on the expression NF-κB-mRNA、NGF-mRNA in the prostatic tissue & serum of rats.
导师张亚强教授是中西医结合泌尿外科专家刘猷枋教授的学术继承人,他在充分继承刘猷枋教授学术经验的基础上,在运用活血化瘀法治疗慢性前列腺炎方面有其独到之处。本论文在对中医治疗慢性前列腺炎历代文献整理基础上,对导师治疗慢性前列腺炎的临床经验,用现代科学手段进行了深入挖掘。同时,以自身免疫性前列腺炎大鼠模型为载体,采用酶联接免疫吸附测定法(ELISA)、实时荧光定量PCR(RT-PCR)等技术,从整体——细胞因子——基因等层次,深入探讨了活血化瘀法及组方丹蒲胶囊治疗慢性前列腺炎的分子机制,从一个侧面揭示了中医药治疗慢性前列腺炎的理论依据和导师临床治验的科学内涵。
一、理论研究
1.历代医家著述对后世慢性前列腺炎的治疗具有指导意义
通过整理祖国医学历代文献对慢性前列腺炎的认识,可以总结出中医对该病的认识可分为四个时期:①秦汉时期为萌芽期,对前列腺炎形成了初步的认识;②隋唐时期是发展期,在原有认识基础上又有了一定的发展,该时期医家对淋证病因病机、治法、方药有了更深一步的描述,尤其是淋证分类出现了七淋、五淋的见解,为以后的发展奠定了坚实的基础;③宋金元时期是充实期,这一时期百家争鸣,产生了很多学术流派,派生出许多学术观点,对“淋、浊、小便不利”的见解更深刻、特点更鲜明;④明清时期是成熟期,是这一疾病的集大成期。明清医家在充分继承前贤学术思想的同时,又结合自己的临床体验,不断地推陈出新,使对“淋”、“浊”、“小便不利”等的认识更加成熟,更加趋于完善。
如何充分挖掘祖国医学文献这一宝库,并以此为切入点,探讨现代中医对慢性前列腺炎辨证论治规律并指导临床,将对当代慢性前列腺炎的中医治疗学的发展产生深远的意义。
2.导师治疗慢性前列腺炎的学术经验
导师在充分继承了刘猷枋教授学术思想的基础上,根据“血瘀贯穿疾病发展始终”的病机特点,临床治疗:①将活血化瘀法作为治疗该病的根本方法,在活血基础上,根据疾病的寒热虚实辨证论治,兼湿热者,佐以清热利湿;兼肾虚者,辅以补肾中药;②根据病程、病情程度论治,轻证多以湿热、血瘀者为多,治以清热利湿、活血止痛;重证或顽固证病程日久,多虚多瘀,在活血益气的基础上,重用三棱、莪术、王不留行、穿山甲等破血化瘀药,同时佐以虫类物如水蛭、地龙等;③注重心理疏导,强调饮食调摄。大量的临床实践表明,长期坚持活血化瘀法中医药治疗能改善患者临床症状(尤其对疼痛的缓解尤为突出),提高患者的生活质量。
二、临床研究
1.借助数据挖掘方法,总结导师治疗慢性前列腺炎的学术经验
利用数据挖掘生物信息学技术,以导师临床诊疗典型病例为研究对象,以保留导师辨证论治特色的结构化的临床数据为基础,以方药为线索,利用频数分析,从多个角度进行分析对比、综合归纳,初步研究名老中医的方——证关系、证——药、症——药关系等,提取导师辨证特点和遣方用药规律等知识,总结导师继承名老专家刘猷枋教授学术思想基础上运用活血化瘀法辨治慢性前列腺炎的学术经验及其理论内涵。
根据90例病历资料分析,展现该病常见临床症状:会阴部不适、尿频、尿不尽、尿后滴白、舌暗红等症状;总结出导师对慢性前列腺炎辨证分为气滞血瘀型、湿热蕴结型、肾虚型3个基本证型,其中,临床两证、三证兼见时有发生。总结出导师治疗慢性前列腺炎常用治法6种、常用药物25味、常用基础方7个、常用的25对药对。在导师常用45味中药功能分类的基础上,归纳出导师在治疗CP的药物使用频次上,活血化瘀药居首位,清热利湿药、补肾药次之,同时采用理气、解表、温里、泻下药等从多方面多层次治疗,说明导师在辨证论治基础上处方,主次分明,脉络清晰。
2丹蒲胶囊治疗慢性前列腺炎的临床研究
目的及方法:采用随机对照的方法对丹蒲胶囊治疗慢性前列腺炎进行再评价。
结论:①丹蒲胶囊治疗慢性前列腺炎的总有效率为83.3%,对照药前列泰片为56.4%,治疗组优于对照组(P＜0.05)。②丹蒲胶囊能明显降低前列腺液白细胞数(EPS-WBC),增加前列腺液卵磷脂小体密度(EPS-CORP)。治疗后两组EPS-WBC均减少,经统计学处理,两组差异有显著性意义,治疗组优于对照组(P＜0.05);治疗后两组EPS-CORP密度较治疗前均可见增加,经统计学处理,两组差异有显著性意义,治疗组优于对照组(P＜0.05)。③丹蒲胶囊能明显改善少腹疼痛、小便频急、尿后余沥不尽、尿道灼热、会阴疼痛、腰骶部疼痛、睾丸疼痛、阴囊潮湿、尿后滴白等单项症状,降低NIH-CPSI评分、NIH-疼痛评分,提高患者生活质量。其中,在降低EPS-WBC、提高EPS-CORP密度,缓解前列腺炎患者少腹疼痛、小便频急、尿后余沥不尽、尿道灼热等症状,以及降低NIH-CPSI评分、NIH-疼痛评分方面,优于对照组(P＜0.05)。进一步证实了丹蒲胶囊能改善能通过改善慢性前列腺炎患者临床症状(尤其对疼痛症状的缓解)、降低NIH-CPSI评分,而达到其治疗作用,研究展示了中医药治疗慢性前列腺炎的优势。
三、实验研究
本课题实验研究以自身免疫性前列腺炎大鼠模型为载体,采用ELISA、RT-PCR等技术,从整体——细胞因子——基因等层次,深入探讨了活血化瘀法及组方丹蒲胶囊治疗慢性前列腺炎的分子机制,从一个侧面揭示了中医药治疗慢性前列腺炎的理论依据和导师临床治验的科学内涵。
1.优选出建立自身免疫性前列腺炎大鼠模型方法——加强免疫法,为研究丹蒲胶囊治疗慢性前列腺炎的分子机制奠定了坚实的实验基础。
2.应用加强免疫法建立实验性自身免疫性前列腺炎大鼠模型,光镜和电镜下观察丹蒲胶囊对模型组织形态学及超微结构的变化。结果表明:模型组光镜表现:前列腺腺体遭到破坏,间质及腺体充满大量弥散的淋巴细胞、单核细胞;电镜表现:腺体破坏,粗面内质网扩张明显,线粒体扩张或呈空泡化,核膜皱缩,细胞器扩张,染色质周边凝聚。模型组病理改变符合前列腺慢性炎症表现。丹蒲胶囊能明显减轻或消除模型大鼠的前列腺组织炎症,其中,大剂量组最优。为丹蒲胶囊的临床疗效提供了病理组织学依据。
3.丹蒲胶囊对复杂的细胞因子网络有免疫调控作用,对IL-1β、IL-2、IL-8均有抑制作用,对高水平的IL-10有降低效应,同时能抑制NF-κB的表达而发挥治疗作用。
4.丹蒲胶囊对自身免疫性前列腺炎模型大鼠前列腺组织NGF有抑制作用,对前列腺组织及血清中的PGE2水平有降低效应,通过这种抑制作用而发挥该药的镇痛效应。
5.自身免疫性前列腺炎大鼠模型出现NF-κB、NGF基因mRNA的高表达,丹蒲胶囊通过抑制NF-κB、NGF基因mRNA的表达发挥治疗效应。研究从基因水平阐释了中药丹蒲胶囊对慢性前列腺炎治疗作用的分子机制。
四、本研究的特色及创新之处
1.临床研究
在临床应用丹蒲胶囊有效的基础上,利用数据挖掘生物信息学技术,以导师临床诊疗典型病例为研究对象,以保留导师辨证论治特色的结构化临床数据为导向,以方药为线索,利用频数分析,从多个角度进行分析对比、综合归纳,初步研究名老中医的方——证关系、证——药、症——药关系等,提取导师辨证特点和遣方用药规律等知识,总结导师在继承名老专家刘猷枋教授学术思想基础上,运用活血化瘀法辨治慢性前列腺炎的学术经验及理论内涵,为深层次继承挖掘名老专家学术经验提供了新思路。未见同类研究报道。
2.实验研究
2.1优选出成功建立实验性自身免疫性前列腺炎大鼠模型的加强免疫法,为进一步探索前列腺炎的自身免疫学说奠定了实验基础,是本研究的特色之一。
2.2以动物前列腺组织及血清为观察对象,以IL-1β、IL-8、IL-10、IL-2、NF-κB、NGF、PGE2等细胞因子为观测指标,研究了丹蒲胶囊这些因子的调节作用,从一个侧面揭示了丹蒲胶囊免疫调节及镇痛作用的分子机制,为活血化瘀法治疗慢性前列腺炎提供了新的实验依据。在前列腺炎疗效机制的系统研究上未见同类报道。
3.理论创新
本课题针对“前列腺炎与细胞因子”的研究热点,首次提出“活血化瘀法及组方丹蒲胶囊可能通过调控NF-κB、NGF的基因mRNA表达而发挥治疗效应”的假说,应用RT-PCR的方法证实丹蒲胶囊对模型大鼠NF-κB、NGF的基因mRNA的表达有抑制效应,验证了假说。研究揭示了活血化瘀法治疗慢性前列腺炎分子基础的科学内涵,为中医药防治慢性前列腺炎的研究提供了新思路。
Chronic Prostatitis(CP) is a common disease in young and middle aged men.It has impact on physical and mental health with the characteristics of symptom complex,longer course,and easy recurrence.How to improve clinical symptoms and increase the clinical efficacy is the most critical topic in the field of CP currently.
Advisor Professor Zhang Ya-qiang is the academic inheritor of Professor Liu You-fang who is the founder of urology combined traditional Chinese and western medicine in China.On the basis of inheriting academic experience of Professor Liu You-fang,Advisor Professor Zhang often obtain a unique efficacy especially in the treatment of chronic prostatitis by applying the method of promoting blood circulation and removing blood stasis.
According to collecting a great deal of the ancient TCM literature on CP,advisor's clinical experience of treating CP is mined thoroughly by means of modern scientific method.Meanwhile,the experimental autoimmune prostatitis(EAP) animal model was adopted.And the modern techniques of Enzyme-Linked Immunosorbent Assay (ELISA),Real-Time polymerase chain reaction(RT-PCR) were applied to detect test targets.
The molecular mechanisms on DanPu capsule in the therapy of CP were explored at different levels from the whole-cytokine-gene.And the scientific content of the theory of TCM treating CP and the clinical experience of the tutor were revealed from one aspect.
PartⅠ:Theoretical studies
1.The ancient literature of TCM having significant meaning in the therapy of Chronic Prostatitis
On the basis of combing a great deal of the ancient TCM literature about CP,the idea of TCM on such disease was divided into four periods:
①It was the sprouting period that during the Qin & Han Dynasties.
②It was the development period in the Sui and Tang Dynasties.
③It was the substantial period that from the Song Dynasty to Yuan Dynasty.
④It was mature period during the Ming and Qing Dynasties.
2.Academic experience on advisor of treating CP
According to the pathogenesis characteristic of "the syndrome of Blood Stasis is crossing the course of CP",on the basis of inheriting the academic thoughts of Pro LIU You-fang,the clinical experiences of my tutor are as follows:
①To advocate major therapeutic method of promoting blood circulation and removing blood stasis in the therapy of chronic prostatitis.
②To treat CP based on different course and state of patients.
③At the same time,to emphasize the importance of adjusting the food,drink and the mental state.
PartⅡ:Clinical studies
1.The clinical study about medication and syndrome on advisor in thetreatment of Chronic Prostatitis
To make use of the bioinformation data mining(DM),and to take advisor's prescription and medicine as the clues,90 pieces of the primitive prescriptions were carried out to analyze from multi-angles.Regularities were summarized as follow:
①Chronic Prostatitis was divided into three basic syndromes by Syndrome differentiation and treatment.
②6 elementary methods,25 common Chinese herbs,6 elementary prescriptions and 25 couple of herbs were summarized respectively.
③According to functional classification of herbs,it was the first place that a kind of drug for removing blood stasis.It was the second place that a kind of the drug for eliminating dampness and heat and a kind of the drug for nourishing the kidney.
2.the clinical research on DanPu capsule in the therapy of CP
Purpose and method:To reevaluate the clinical efficacy of DanPu capsule treating CP by means of randomized controlled trial(RCT).
Conclusions:①The total effective rate of DanPu capsule and the control drug were 83.3%and 56.4%respectively.The effect in DanPu capsule group is better than that of the control group(P＜0.05).
②DanPu capsule can reduce the white blood count in expressed prostatic secretion(EPS) and increase the lecithin corpuscle count of EPS,which is superior to the control group.
③DanPu capsule can improve clinical symptoms such as pain in the lower abdomen,frequent urination,burning urethra,perineal pain,lumbosacral pain, testicular pain,scrotum humidity and so on.Besides,It can also lower NIH-CPSI (National Institutes of Health Chronic Prostatitis Symptom index),NIH-pain-score and elevate the quality of life.
PartⅢexperimental research
The modern techniques of ELISA and RT-PCR were applied to detect the lab indexes.From the different layers of the whole-cytokine-gene,to explore extremely the molecular mechanisms of DanPu capsule in the therapy of CP.
From one aspect,the scientific content of was brought to light,which were the theories of TCM and the clinical experience of the advisor.
1.Selecting the stable method of establishing experimental autoimmune prostatitis(EAP) animal model—booster immunization.
2.Under light microscope and electron microscope,it is found that DanPu capsule can lessen and eliminate the prostatic inflammation of EAP rat model.
3.DanPu capsule has the inhibitory action on IL-1β,IL-2,IL-8 levels in the prostatic tissue and serum of rats.Meanwhile,it has the descending effect on IL-10 and NF-κB(Nuclear Factor-κB) as well.
4.DanPu capsule has the depressant effect on NGF,PGE2 levels in the prostatic tissue & serum of rats.
5.DanPu capsule has the inhibitory action on the expression NF-κB-mRNA、NGF-mRNA in the prostatic tissue & serum of rats.
引文
[1]翟亚春.非细菌性前列腺炎中医证治研究.江苏中医,2001,22(9):9-12.
[2]李曰庆.前列腺疾病临床荟萃.北京:华夏出版社,1996.P7-8.
[3]王劲松,徐福松.再论精室当为奇恒之腑.辽宁中医杂志,2002,29(10):590.
[4]李德新.中医基础理论.北京:人民卫生出版社,2001.P93.
[5]张家锡.中医学基础.上海:上海科学技术出版社,2001.P54.
[6]吴丽丽,严灿,王文竹.中医脏腑功能与生殖.甘肃中医,2004,17(4):4-6.
[7]姜志戎.精室当属男子奇恒之腑刍议.吉林中医药,2003,23(2):5.
[8]李益生.论男性奇恒之腑.中国中医基础医学杂志,2002,8(4):19-21.
[9]吴阶平.吴阶平泌尿外科学.济南:山东科学技术出版社,2004.P1989.
[10]邢国红.施汉章教授治疗慢性前列腺炎经验介绍.新中医,2004,36(5):11-12.
[11]徐福松,陈乃光.慢性前列腺炎诊断疗效标准.成都:中华中医药学会男科学会第三届学术研讨会论文汇编,1998.P179-181.
[12]王琦.王琦男科学.郑州:河南科学技术出版社,2007.P645-646.
[13]国家中医药管理局.中华人民共和国中医药行业标准·中医病证诊断疗效标准.南京:南京大学出版社,1994.P50.
[14]郑筱萸.中药新药临床研究指导原则.北京:中国医药科技山版社,2002.P168-169.
[15]李兰群,王传航,刘春英.慢性前列腺炎中医证型分布频率研究.中华中医药杂志,2005,20(4):245-246.
[16]刘步平.广州市高校男生慢性前列腺炎中医证型分布规律的调查研究.中华男科学,2007,13(9):810-814.
[17]宋竖旗.张亚强从瘀论治慢性前列腺炎的经验.中国中医基础医学杂志,2007,13(8):609-615.
[18]姚实林.王琦从络论治前列腺痛的经验.中医杂志,2007,48(2):114-115.
[19]郭小鹏,崔崎,马超.络病学说在慢性前列腺炎治疗中的运用.新疆中医药,2004,22(2):20-22.
[20]郑胜.张敏建教授从肝论治慢性前列腺炎的经验.福建中医药,2007,38(1):15-16.
[21]张敏建.慢性前列腺炎从相火论治.江苏中医药,2006,27(5):3-4.
[22]程宛钧.张敏建老师从相火论治慢性前列腺炎经验.福建中医学院学报,2006,16(2):62-64.
[23]吕生辉,李湛民.从三焦论治前列腺炎.山西中医学院学报,2006,7(1):15-16.
[24]张春和.“诸痛痒疮,皆属于心”理论在治疗男科病中的应用举隅.云南中医学院学报,2006,29(2):35-36.
[25]白遵光,陈志强,王树声,等.从内痈论治慢性非细菌性前列腺炎/慢性盆腔疼痂综合征的临床观察.中国男科学杂志,2006,20(3):55-57.
[26]张迎春.从脾胃论治无菌性前列腺炎.中国中医药信息杂志,2006,13(6):88.
[27]何映.以”风胜湿”理论论治慢性前列腺炎.江苏中医药,2006,27(5):4-5.
[28]梁沛华,崔建锋,邓宾,等.从经筋论治Ⅲ型前列腺炎的临床研究.广州中医药大学学报,2005,22(5):348-351.
[29]付伟.试述奇经理论与男科实践.中国中医基础医学杂志,2001,7(5):13-14.
[30]李波,江立军.疏润任脉法治疗非细菌性前列腺炎临床观察.中国中西医结合杂志,2003,23(1):70-71.
[31]冯子驹.从肝论治慢性非细菌性前列腺炎128例.新中医,2007,39(7):67-68.
[32]王润林,梁生旺.慢性前列腺炎的中医分型和综合治疗.光明中医,2006,21(7):21-23.
[33]徐彩华,冷风翠,相亚杰.辨证治疗慢性前列腺炎49例.山东中医杂志,2006,25(8):535.
[34]王黎君,徐大鹏,赵继福,等.辨证治疗慢性前列腺炎683例疗效观察.中华中医药杂志,2005,20(12):757-758.
[35]邹方伟,姜兆友,霍振国.辨证施治慢性前列腺炎102例.山东中医杂志,2003,22(5):285-286.
[36]刘步平,谢建兴.红藤清前汤治疗慢性前列腺炎267例总结.湖南中医杂志,2007,23(2):26.
[37]陈磊,夏卫平,周智恒,等.红鹿合剂治疗慢性非细菌性前列腺炎的临床研究.上海中医药杂志,2006,40(4):29-30.
[38]任云峰.马鞭草冲剂治疗ⅢA型前列腺炎综合征42例.陕西中医,2005,26(8):788-789.
[39]谢坚,李慈春.加味血府逐瘀汤治疗慢性非细菌性前列腺炎80例临床观察.中国男科学杂志,2004,18(3):36-38.
[40]游峰.萆薜化浊汤治疗慢性前列腺炎34例.辽宁中医学院学报,2004,6(4):302.
[41]徐罡,鲁军,唐孝达.前列安栓治疗慢性前列腺炎:多中心双盲随机安慰剂对照试验.中华泌尿外科杂志,2002,23(5):296-298.
[42]宋严冬,王升,马忠萍.野菊花栓治疗慢性前列腺炎疗效观察.吉林中医药,2005,25(2):29.
[43]任棣.中药直肠栓治疗慢性前列腺炎82例.中国中医药信息杂志,2002,9(3):49.
[44]马杰,韩鸿雁,李尔辉.前列栓治疗慢性前列腺炎40例.中国中医急症,2002,11(6):492-493.
[45]周仕轶,王林,熊国斌.五味消毒饮加减灌肠治疗前列腺炎综合征30例疗效观察.四川中医,2006,24(6):50-51.
[46]李瑞.中药保留灌肠治疗慢性非细菌性前列腺炎48例.中医外治杂志,2006,15(6):30.
[47]莫天栩.中药灌肠及口服治疗慢性前列腺炎50例.中国中医急症,2005,14(9):839.
[48]崔飞禅,苏斌,蔡东华.中药灌肠加外敷治疗慢性非细菌性前列腺炎52例.新中医,2004,36(7):67.
[49]桂文进.中药口服与坐浴治疗非细菌性前列腺炎30例.吉林中医药,2003,23(3):19-20.
[50]徐想德.癃舒汤内服坐浴治疗慢性前列腺炎.湖北中医杂志,2002,24(7):45.
[51]曾晔,赖海标,钟亮,等.坐盆汤坐浴治疗慢性非细菌性前列腺炎的临床观察.中医外治杂志,2005,14(2):16-17.
[52]李儒文,肖萍.解毒化瘀汤配合中药离子导入法治疗慢性前列腺炎.湖北中医杂志,2006,28(8):35.
[53]汪胤.离子导人法冶疗慢性前列腺炎50例.湖北中医杂志,2004,26(2):46.
[54]何天有,赵耀东,雒成林.针刺”三阴穴”治疗慢性前列腺炎临床观察.中国针灸,2004,24(10):697-698.
[55]王铠.针灸辨证治疗慢性前列腺炎30例.四川中医,2002,20(1):72-73.
[56]初艳玲,尚艳杰.针灸治疗慢性前列腺炎31例.针灸临床杂志,2005,21(2):21-22.
[57]薛银萍,张士斌,高彤.温针灸为主治疗慢性前列腺炎疗效观察.中国针灸,2006,26(5):335-336.
[58]于漾,康井利.温针灸治疗慢性前列腺炎临床研究.辽宁中医杂志,2004,31(9):775-776.
[59]吴宏东,孙自学.芒针合前列舒丸治疗慢性前列腺炎临床观察.安徽中医学院学报,2006,25(5):21-23.
[60]杨铭.芒针治疗慢性前列腺炎68例.针灸临床杂志,2004,20(6):23.
[61]田华张,张永东,朴明武.针灸配合中药治疗慢性前列腺炎体会.中医药学刊,2006,24(5):950.
[62]宋竖旗.针药结合治疗慢性非细菌性前列腺炎56例.中医研究,2005,18(7):53-54.
[63]马久太,赵明君,卢新义.前列舒通胶囊合用喹诺酮类抗生素治疗慢性细菌性前列腺炎100例临床研究.中医杂志,2006,47(12):915-916.
[64]王万春,严张仁.中西医结合治疗慢性前列腺炎50例疗效评价.光明中医,2006,21(5):42-43.
[65]刘大伟.中西医结合治疗慢性前列腺炎150例.辽宁中医杂志,2006,33(6):716-717.
[66]罗永革,罗永新.中西医结合治疗慢性前列腺炎/慢性盆腔疼痛综合征临床观察.现代泌尿外科杂志,2006,11(2):114-115.
[67]张晓毅,周桂琴,郭英.中西医结合治疗慢性前列腺炎的疗效观察.中国中医基础医学杂志,2006,12(3):225-226.
[68]张德建,陈平,程怀瑾.中西医结合治疗慢性前列腺炎167例临床观察.中西医结合学报,2006,4(4):420-422.
[69]王和.前列腺炎.贵阳:贵州科学技术出版社,2001.P202-237.
[70]陈志强,吴清和,王树声.前列清抑菌、抗炎和改善微循环作用的实验研究.广州中医大学学报,2000,17(2):147.
[71]陆原,陈达灿,李强.中药尿路清对临床不同血清型解脉支原体及其耐药菌株的药敏实验.中华男科学,2002,8(2):512.
[72]国家中医药管理局(中华本草)编委会.中华本草.上海:上海科技出版社,1998.
[73]张敏建,褚克丹,程心玲,等.艾可合剂对小鼠抗炎镇痛作用的实验研究.中华男科学,2007,13(5):471-473.
[74]李正东,蒋学洲,夏正平.摄护宁胶囊治疗无菌性前列腺炎实验研究.中国中西医结合外科杂志,1999,5(2):46.
[75]许涛,戴宁,江安红.男炎消对大鼠实验性前列腺炎影响的病理学观察.安徽中医学报,2001,20(1):38-39.
[76]贺菊乔,朱晓明,曹晖.紫金胶囊治疗大鼠细菌性前列腺炎的实验研究.中国中医药科技,2000,7(2):72.
[77]张亚强,刘猷枋.前列腺方治疗慢性前列腺炎血瘀证的临床与实验研究.中国中西医结合杂志,1998,18(9):534-536.
[78]蒋毅,王久源.中药前必治治疗慢性前列腺炎的临床研究.中国中医基础医学杂志,1999,6(1):14.
[79]朱琦,薛慈民.慢性前列腺炎病人的尿动力学变化和治疗.中华男科学,2001,7(3):185-188.
[80]Mehik A,Hellstrom P,Lukkarinen O,etal.Increased intraprostatic pressure in patients with chronic prostatitis.Urol Res,1999,27(4):277-279.
[81]邓春华,梁宏,梅骅,等.前列腺内尿液返流在慢性前列腺炎发病中的作用.中华泌尿外科杂志,1998,19(6):288-289.
[82]张蜀武,常德贵,王久源.通关胶囊对离体人增生前列腺α1-AR的拮抗作用.中华男科学,2001,7(3):136.
[83]郝重耀.针剌“培精祛毒方”对慢性前列腺炎及前列腺痛患者尿流率的影响.针灸临床杂志,2001,17(12):13-14.
[84]慈健,刘树民,宫大鑫.前列安栓对慢性前列腺炎和良性前列腺增生症患者尿流率的影响.中国男科学杂志,2003,17(2):129-130.
[85]郭应禄,李宏军.前列腺炎.北京:人民军医出版社,2007.P92-93.
[86]周青,贺菊乔,田雪飞,等.紫金胶囊对细菌性前列腺炎模型大鼠炎性因子的影响.中国中医药信息杂志,2006,13(9):30-32.
[87]张亚强,卢建新,吴志奎,等.丹蒲胶囊对慢性前列腺炎患者前列腺液IL-2、IL-6水平的影响.中国中西医结合杂志,2002,22(11):828-829.
[88]张亚强.中药前列腺汤对实验性前列腺炎病理模型的影响.中国中西医结合杂志,1991,17(11):483-484.
[89]蒋毅,王久源.中药前必治治疗慢性前列腺炎的临床研究.中国中医基础医学杂志,1999,6(1):14-16.
[90]王瑞,张卫星,郑涛,等.前列腺按摩液pH测定在慢性前列腺炎中的临床应用价值.中华男科学,2004,10(8):630-631.
[91]徐福松,曹开镛.男科基础与临床.北京:中国科学技术出版社,1996.P58-68.
[92]林成仁,王敏,刘建勋.前列安栓在大鼠体内的药代动力学研究.中华男科学,2000,6(2):107-110.
[1]Rizzo M,Marchetti F,Travaglini F,etal.Clinical characterization of the prostatitis patient in Italy:a prospective urology outpatient study.World J Urol.2005,23(1):61-66.
[2]Mehik A,Hellstrom P,Lukkarinen O,et al.Epidemiology ofprostatitis in Finnish men:a population-based cross-sectional study.BJU Int,2000,86:443-448.
[3]Krieger JN,Riley DE,Cheah PY,et al,Epidemiology of prostatitis:new evidence for a world-wide problem,World J Urol,2003,21:70-74.
[4]郭应禄,李宏军.前列腺炎.北京:人民军医出版社.2007.P68-92.
[5]梁朝朝.慢性前列腺炎流行病学及其发病机制的研究.安徽医科大学博士学位论文.2005.P1.
[6]夏同礼,孔祥田,宓培,等.我国成人前列腺非特异性炎.中华泌尿外科志,1995,16:711-713.
[7]EV Vykhovanets,MI Resnick,GT MacLennan,et al.Experimental rodent models of prostatitis:limitations and potential.Prostate Cancer and Prostatic Diseases.2007,10(1):15-29.
[8]陈昭典.前列腺炎综合征的历史演变与进展.中国男科学杂志,2003,17(6):363.
[9]McNaughton Collins M,MacDonald R,Wilt TJ.Diagnosis and treatment of chronic abacterial prostatitis:a systematic rewiew.Ann Intern Med,2000,133(5):367-381.
[10]Riley DE,Berger RE,Miner DC,et al.Diverse and related 16SrRNA- encoding DNA sequences in prostate tissues of men with chronic prostatitis.J Clin Microbiol,1998,36(6):1646-1652.
[11]Krieger JN,Riley DE,Vessella RL,etal.Bacterial in DNA sequences in prostate tissue from patients with prostate cancer and chronic prostatitis.J Urol,2000,164(4):1221-1228.
[12]谢辉黄,慧聪,杨亦荣,等.成年人前列腺组织细菌16s rRNA基因的检测.中华医学杂志.2006,86(14):976-978.
[13]邓春华,梁宏,梅骅,等.前列腺内尿液返流在慢性前列腺炎发病中的作用.中华泌尿外科杂志,1998,19(6):288-289.
[14]Batstone GR,Doble A,Gaston JS.Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome(CPPS).Clin Exp Immunol,2002,128(2):302-307.
[15]Miller LJ,Fischer KA,Goralnick SJ,et al.Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome.Urology,2002,59(4):603-8.
[16]Nadler RB,Koch AE,Calhoun EA,etal.IL-lbeta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis.JUrol,2000,16(1):214-218.
[17]刘海红,夏欣一,吴永明,等.慢性非细菌性前列腺炎慢性骨盆疼痛综合征患者外周血TH1/TH2细胞的检测.中华男科学杂志,2006,12(4):330-332.
[18]Persson BE,Ronquist G.Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion.J Urol.1996,155(3):958-60.
[19]Kirby RS,Lowe D,Bultitude MI,et al.Intra-prostatic urinary reflux:an aetiological factor in abacterial prostatitis.Br J Urol,1982,54(6):729-31.
[20]张华江,张建龙.慢性前列腺炎患者心理状况调查.临床精神医学杂志,2006,6(6):365.
[21]李海成,阮元峰,陈联大,等.慢性前列腺炎患者心理障碍调查分析.齐齐哈尔医学院学报,2006,27(11):1283-1284.
[22]杨金瑞,刘龙飞.中国泌尿外科医师对慢性前列腺炎患者精神症状的认知及诊治行为调查.中国心理卫生杂志,2007,21(6):416.
[23]武立新,梁朝朝.慢性前列腺炎与精神障碍.中华男科学杂志,2005,11(10):780-783.
[24]Zhou JF,Xiao WQ,Zheng YC,Dong J,Zhang SM.Increased oxidative stress and oxidative damage associated with chronic bacterial prostatitis.Asian J Androl,2006,8(3):317-323.
[25]刘小平,邓岩.氧自由基在慢性前列腺炎发病中的作用.中国男科杂志,2001,15(4):254.
[26]董杰,郑一春,肖伟强,等.慢性细菌性前列腺炎与氧化应激加剧和氧化损伤的关系.中华泌尿外科杂志,2006,27(增刊2):69-73.
[27]周占松,宋波,卢根生,等.前列腺炎性疼痛与脊髓星形胶质细胞活化关系的研究.第三军医大学学报,2005,27(18):1853-1854.
[28]陈勇,宋波,熊恩庆,等.前列腺与会阴盆底联系的电刺激研究.中华泌尿外科杂志,2004,25(2):124-126.
[29]Shahed AR,Shoskes DA.Correlation of beta-endorphin and prostaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response.J Urol,2001,166(5):1738-1741.
[30]周占松,宋波,卢根生,等.慢性前列腺炎牵涉痛神经机制及其与膀胱、盆底肌的关系.解放军医学杂志,2005,30(12):1055-1057.
[31]Riley DE,Krieger JN.X Chromosomal short tandem repeat polymorphisms near the phosphoglycerate kinase gene in men with chronic prostatitis.BiochimBiophys Acta,2002,1586:99-107
[32]周任远,张燕宾.不同类型慢性前列腺炎前列腺液锌含量的分布及意义.临床泌尿外科杂志,2004,19(3):168-169.
[33]Drach GW,Fair WR,Meares EM,Stamey TA.Classification of benign diseases associated with prostatic pain:prostatitis or prostatodynia?J Urol.1978,120:266.
[34]Schaeffer AJ,Knauss JS,Landis JR,et al.Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis:the National Institutes of Health Chronic Prostatitis Cohort Study.J Urol,2002,168(3):1048-1053.
[35]吴阶平.吴阶平泌尿外科学.济南:山尔科学技术出版社,2004.P389-390.
[36]Krieger JN,Ross SO,Deutsch LA,et al.Counting leukocytes in expressed prostatic secretions from patients with chronic prostatitis/chronic pelvic pain syndrome.Urology,2003,62(1):30-34.
[37]Nickel JC.Prostatitis and related conditions.In:Walsh PC.Eds.Compbell's Urology.8 th ed.Philadelphia:Saunders.2002,603-630.
[38]Seiler D,Zbinden R,Hauri D,et al.Four-glass or two glass test for chronic prostatitis.Urologe A,2003,42(2):238-242.
[39]那彦群.中国泌尿外科疾病诊断治疗指南.北京:人民卫生出版社,2007.P223-225.
[40]Nadler RB,Collins MM,Propert KJ,et al.Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome.Urology,2006,67(2):337-342.
[41]刘猷枋,张亚强.中西医结合泌尿外科学.北京:人民卫生出版社,2007.P246
[42]Propert KJ,McNaughton-Collins M,Leiby BE,et al.A prospective study of symptoms and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome:the National Institutes of Health Chronic Prostatitis Cohort study.J Urol,2006,175(2):619-623.
[43]Cheah PY,Liong ML,Yuen KH,et al.Reliability and validity of the National Institutes of Health:Chronic Prostatitis Symptom Index in a Malaysian population.World J Urol,2006,24(1):79-87.
[44]吴阶平.吴阶平泌尿外科学.济南:山东科学技术出版社,2004.P584-586.
[45]Bundrick W,Heron SP,Ray P,et al.Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis:a randomized double-blind multicenter study.J.Urology,2003,62(3):537-541.
[46]Skerk V,Marekovic I,Markovinovic L,et al.Comparative randomized pilot study of azithromycin and doxycycline efficacy and tolerability in the treatment of prostate infection caused by Ureaplasma urealyticum.Chemotherapy,2006,52(1):9-11.
[47]李昕,李宁忱,丁强,等.α1肾上腺素能受体阻滞剂荼哌地尔治疗慢性非细菌性前列腺炎的临床研究.中华男科学杂志,2006,12(3):234-236.
[48]Mehik A,Alas P,Nickel JC,et al.Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome:a prospective,randomized,double-blind,placebo-controlled,pilot study.Urology,2003,62(3):425-429.
[49]Nickel JC,Narayan P,McKay J,et al.Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin:a randomized double blind trial.J Urol,2004,171(4):1594-1597.
[50]Evliyaoglu Y,Burgut R.Lower urinary tract symptoms,pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin;versus placebo.Int Urol Nephrol,2002,34(3):351-356.
[51]沈柏华,金晓东,蔡松良,等.α1受体阻滞剂联合抗生素治疗慢性前列腺炎疗效及机制.中华男科学杂志.2004,10(7):518-520.
[52]曾晓勇,叶章群,杨为民,等.塞来昔布治疗ⅢA型前列腺炎的临床评估.中华男科学杂志,2004,10(4):278-281.
[53]惠继红,单玉喜,阳东荣,等.塞来昔布对ⅢB型前列腺炎患者前列腺液中细胞因子的影响及临床评估.中国男科学杂志,2007,21(10):21.
[54]李宁忱,那彦群,郭宏骞,等.舍尼通治疗慢性非细菌性前列腺炎的临床研究.中华泌尿外科杂志,2003,24(9):635-637.
[55]Kaplan SA,Volpe MA,Te AE.A Prospective,1-Year Trial Using Saw Palmetto Versus Finasteride in the Treatment of Category Ⅲ Prostatitis-Chronic Pelvic Pain Syndrome.J Urol,2004,171(1):284-288.
[56]Elist J.Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome:a randomized,double-blind,placebo-controlled study.Urology,2006,67(1):60-63.
[57]乔博义.氟西汀协同治疗伴情绪障碍的慢性前列腺炎.中华男科学杂志,2004,10(2):145-146.
[58]蔡岳斌.曲唑酮治疗非细菌性前列腺炎的疗效观察.中国男科学杂志,2004,18(5):41-42.
[59]曾宪辉,冯俊铎,蒋东朋.α1受体阻断剂联合抗抑郁药治疗前列腺痛的效果.中华泌尿外科杂志,2005,26(5):351.
[60]Kastner C,Hochreiter W,Huidobro C,et al.Cooled transurethral microwave thermotherapy for intractable chronic prostatitis-results of a pilot study after 1 year.Urology,2004,64(6):1149-1154.
[61]Chiang PH,Chiang CP.Therapeutic effect of transurethral needle ablation in non-bacterial prostatitis:chronic pelvic pain syndrome type Ⅲa.Int J Urol,2004,11(2):97-102.
[62]杰瓦德,杨为民.生物反馈技术治疗慢性盆底疼痛综合征及慢性前列腺炎.临床泌尿外科杂志,2003,18(10):606-607.
[63]王振声,赵庆利,白强,等.慢性非细菌性前列腺炎的手术治疗(附102例报告).中华泌尿外科志,2000,21(12):746-748.
[64]武立新,梁朝朝,唐智国,等.前列腺液白细胞计数与临床症状的相关分析.中华泌尿外科杂志,2006,27(3):194196.
[65]李宏军,商学军,黄宇烽.IL-10、IL-8在慢性前列腺炎中的改变及意义.中华男科学杂志,2004,10(7):486-488.
[66]夏国守,何映,缪界平,等.前列腺按摩液IL-8测定在Ⅲ型前列腺炎分型中的临床意义.中国男科学杂志,2007,21(8):41-43.
[67]王瑞,郑涛,王祖龙.不同症状慢性前列腺炎患者前列腺按摩液pH值、卵磷脂小体与白细胞数比较.郑州大学学报(医学版),2006,41(5):947-948.
[68]王瑞,张卫星,郑涛,等.前列腺按摩液pH测定在慢性前列腺炎中的临床应用价值.中华男科学杂志,2004,10(8):630-631.
[69]郝宗耀,梁朝朝,张学军,等.慢性前列腺炎患者前列腺液、尿液电解质测定及其相关性研究.中华泌尿外科杂志,2004,25(7):465-468.
[1] Honda H, Miharu N, Ohashi Y, et al. Fetal gender determination in early pregnancy through qualitative and quantitative analysis of fetal DNA in maternal serum. Hum Genet, 2002,110(1):75-79.
[2] Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol, 2004,172(3):839-845.
[3] Lange U, Teichmann J. Ankylosing spondylitis and genitourinary infection. Eur J Med Res, 1999,4(1): 1-7.
[4] Chernyshov VP. Lymphocyte response to phytomitogens in comparison to autoimmune reactions and the state of spermatogenesis in uro(urethro)genic experimental prostatitis in dogs. Fiziol Zh, 1979,25(3):286-296.
[5] Robinette CL. Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. Prostate, 1988,12(3):271-286.
[6]魏武然,张唯力,戴君永．人鼠模型非细菌性前列腺炎模型的建立．中国男科学杂志, 2006,20(1)：22—24．
[7] Casas-Ingaramo A, Depiante-Depaoli M, Pacheco-Rupil B. Activation of cytotoxic cells by syngeneic prostate antigens in experimental autoimmune vesiculo-prostatitis. Autoimmunity, 1991,9(2): 151-157.
[8] Keetch DW, Humphrey P, Ratliff TL. Development of a mouse model for nonbacterial prostatitis. J Urol, 1994,152(1):247.
[9] Maccioni M, Rivero VE, Riera CM. Prostatein (or rat prostatic steroid binding protein) is a major autoantigen in experimental autoimmune prostatitis. Clin Exp Immunol, 1998,112(2):159-165.
[10] Rivero V, Carnaud C, Riera CM. Prostatein or steroid binding protein (PSBP) induces experimental autoimmune prostatitis (EAP) in NOD mice. Clin Immunol, 2002,105(2): 176-184.
[11] Penna G, Amuchastegui S, Cossetti C, etal. Spontaneous and prostatic steroid binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic mouse. J Immunol, 2007,179(3):1559-1567.
[12] Lang MD, Nicke IJC, Olson ME, etal. Rat model of experimentally induced abacterial Prostatitis. Prostate, 2000,45(3):201.
[13] Alexander RB, Ponniah S, Hasday J, etal. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology, 1998,52(5):744-749.
[14] John H, Barghom A, Funke G, etal. Noninflammatory chronic pelvic pain Syndrome immunological study in blood , ejaculate and prostate tissue. European Urology, 2001,39(1):72.
[15] Ponniah S, Arah I, Alexander RB. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate, 2000,44(1 ):49-54.
[16] Shoskes DA, Albakri Q, Thomas K, et al. Cytokine polymorphisms in men with chronic prostatitis/chronic pelvic pain syndrome: association with diagnosis and treatment response. J Urol,2002,168(1):331-335.
[17]Batstone GR,Doble A,Gaston JS.Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome(CPPS).Clin Exp Immunol,2002,128(2):302-307.
[18]顾方六.现代前列腺病学.北京:人民军医出版社,2003.P526.
[19]Razumov SV,Medvedev AA,Chirun NV,etal.Role of cytokines in the diagnosis of chronic prostatitis.Urologiia,2003(6):25-28.
[20]Miller LJ,Fischer KA,Goralnick SJ,et al.Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome.Urology,2002,59(4):603-608.
[21]Penna G,Mondaini N,Amuchastegui S,et al.Seminal plasma cytokines and chemokines in prostate inflammation:interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.Eur Urol,2007,51(2):524-533.
[22]Shoskes DA,Albakri Q,Thomas K,et al.Cytokine polymorphisms in men with chronic prostatitis/chronic pelvic pain syndrome:association with diagnosis and treatment response.J Urol,2002,168(1):331-335.
[23]段志国,杨为民.细胞因子与慢性前列腺炎关系的研究现状.中国男科学杂志,2005,19(1):57-59.
[24]Jang TL,Schaeffer AJ.The role ofcytokines in prostatitis.World J Urol,2003,21(2):95-99.
[25]Dinarello CA.Proinflammatory cytokines.Chest,2000,118(2):503-508.
[26]Nadler RB,Koch AE,Calhoun EA,et al.IL-lbeta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis.J Urol,2000,164(1):214-218.
[27]Alexander RB,Ponniah S,Hasday J,et al.Elevated levels of proinflammatory cytokines in the semen of patients with Chronic prostatitis/chronic pelvic pain syndrome.Urology,1998,52(5):744-749.
[28]Paulis G,Conti E,Voliani S,et al.Evaluation of the cytokines in genital secretions of patients with chronic prostatitis.Arch Ital Urol Androl,2003,75(4):179-186.
[29]John H,Maake C,Barghorn A,et al.Immunological alterations in the ejaculate of chronic prostatitis patients:clues for autoimmunity.Andrologia,2003,35(5):294-299.
[30]Hochreiter WW,Nadler RB,Koch AE,et al.Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions.J Urol,2005,174(2):589.
[31]Penna G,Mondaini N,Amuchastegui S,et al.Seminal plasma cytokines and chemokines in prostate inflammation:interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.Eur Urol,2007,51(2):524-533.
[32]Miller LJ,Fischer KA,Goralnick SJ,et al.Interleukin-10 levels in seminal plasma:implications for chronic prostatitis/chronic pelvic pain syndrome.J Urol,2002,167(2 Pt 1):753-756.
[33]John H,Maake C,Barghorn A,et al.Immunological alterations in the ejaculate of chronic prostatitis patients:clues for autoimmunity.Andrologia,2003,35(5):294-299.
[34]李宏军,商学军,黄宇烽.IL-10、IL-8在慢性前列腺炎中的改变及意义.中华男科学杂 志,2004,10(7):486-487.
[35]段志国,杨为民.前列腺炎患者前列腺液中IL-2、IL-8及IL-10的水平分析.中华男科学,2005,11(3):201-203.
[36]高英茂.组织学与胚胎学.北京:人民卫生出版社,2001.P107.
[37]Lowe EM,Anand P,Terenghi G,et al.Increased nerve growth Factor Levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis.J Urol,1997,79(4):572-577.
[38]Gonzalez RR,Fong T,Belmar N,et al.Modulating bladder neuro-inflammation:RDP58,a novel anti-inflammatory peptide,decreases inflammation and nerve growth factor production in experimental cystitis.J Urol,2005,173(2):630-634.
[39]蔡川川,杨日东,吴志华.细胞因子与前列腺炎.岭南皮肤性病科杂志,2004,11(3):309-311.
[40]Shahed AR,Shoskes DA.Correlation of β-endorphin and proslaglandinE2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response.J Urol,2001,166(5):1738-1741.
[41]郑国光.核因子κB与炎症和肿瘤.白血病·淋巴瘤,2005,14(5):290-295.
[42]李永春.核因子-κB与炎症性疾病.国外医学·内科学分册,2000,27(11):488-491.
[43]刘海红,夏欣一,吴永明,等.慢性仆细菌性前列腺炎/慢性骨盆疼痛综合征患者外周血Th1/Th2细胞的检测.中华男科学,2006,12(4):330-333.
[44]王红艳.自身免疫性疾病中TH1/TH2细胞平衡.国外医学免疫学分册,2000,23(6):348-350.
[1]Krieger JN,Riley DE,Cheah PY,et al.Epidemiology of prostatitis:new evidence for a world-wide problem.World J Urol,2003,21:70-74.
[2]EV Vykhovanets,MI Resnick,GT MacLennan,et al.Experimental rodent models of prostatitis:limitations and potential.Prostate Cancer and Prostatic Diseases,2007,10(1):15-29.
[3]Jang TL,Schaeffer AJ.The role ofcytokines in prostatitis.World J Urol,2003,21(2):95-99.
[4]吴阶平.吴阶平泌尿外科学.济南:山东科学技术出版社,2004.P583.
[5]张前,刘宁.吲哚美辛治疗慢性菲细菌性前列腺炎/慢性骨盆疼痛综合征患者疼痛的研究.中华泌尿外科杂志,2003,24(6):422.
[6]于勒渝,张秀英,毕振春,等.丹蒲胶囊对试验性慢性前列腺炎的病理学和免疫组织化学研究.中国中西医结合外科杂志,2002,8(5):365-368.
[7]卢建新,高筱松,庞然,等.丹蒲胶囊对大鼠细菌性前列腺炎病理模型的影响.中国中西医结合杂志,2003,23(3):204-206.
[8]张亚强,刘猷枋.前列腺方治疗慢性前列腺炎血瘀证的临床与实验研究.中国中西医结合杂志,1998,18(9):534-535.
[9]张亚强,卢建新,高筱松,等.丹蒲胶囊对前列腺炎组织细胞结构和DNA荧光强度的影响.中国中医药信息杂志,2003,10(8):38-39.
[10]张亚强,卢建新,吴志奎,等.丹蒲胶囊对慢性前列腺炎患者前列腺液IL-2、IL-6的影响.中国中西医结合杂志,2002,22(11):828-830.
[1]王勒渝,张秀英,毕振春,等.丹蒲胶囊对试验性慢性前列腺炎的病理学和免疫组织化学研究.中国中西医结合外科杂志,2002,8(5):365-368.
[2]卢建新,高筱松,庞然,等.丹蒲胶囊对大鼠细菌性前列腺炎病理模型的影响.中国中西医结合杂志,2003,23(3):204-206.
[3]张亚强,卢建新,高筱松,等.丹蒲胶囊对前列腺炎组织细胞结构和DNA荧光强度的影响.中国中医药信息杂志,2003,10(8):38-39.
[4]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P779-782.
[5]温薇.丹参的药理作用及临床应用.中医药信息,2007,24(4):54-55.
[6]孙吉兰,常云亭,宋海英,等.丹参的体外抑菌研究.时珍国医国药,2003,14(12):725.
[7]杨继英,郑军.丹参素的药理作用研究进展.中华临床医学杂志,2007,8(4):45-47.
[8]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P546-548.
[9]石宏志,高南南,李勇枝,等.泽兰有效部分对血小板聚集和血栓形成的影响.中草药,2003,34(10):923-926.
[10]石宏志.泽兰对血液流变学影响的研究与进展.中国临床康复,2004,8(34):7776-7777.
[11]冯英菊,谢人明,陈光娟,等.泽兰镇痛、镇静及对实验性肝再生作用研究.陕西中医,1999,20(2):86-87.
[12]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P219-222.
[13]张芳,陈彦,苏显中.赤芍提取物体外抑菌活性的研究.徐州医学院学报,2006,26(5):418-420.
[14]雷玲,胡竟一,余悦,等.赤芍的抗内毒素作用研究.中药药理与临床,2006,22(6):32-34.
[15]孙大军,祁功才,吕文伟,等.赤芍总苷对实验性血栓形成的影响及其作用机制.中国老年学杂志,2006,26(8):1080-1081.
[16]徐红梅,刘青云.赤芍总苷对大鼠血液流变学的影响.中国中医药信息杂志,2002,9(11):17-19.
[17]朴田,莫晓燕,林瑞峥.赤芍总苷提取液体外清除自由基和抗凝血活性的研究.中国药房,2007,18(9):643-646.
[18]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P540-544.
[19]林小明.桃仁化学成分和药理作用研究进展.蛇志,2007,19(2):130-132.
[20]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P544-546.
[21]金鸣,高子淳,王继峰.羟基红花黄色素A抑制PAF诱发的家兔血小板活化的研究.北京中医药大学学报,2004,27(5):32.
[22]陈志强,王万强,叶秀云,等.红花注射液对脑缺血/再灌注损伤家兔血清白细胞介素IL-8的影响.中国急救学,2005,25(2):118.
[23]杨丽华,张敏,马春,等.红花的现代研究进展.中国老年学杂志,2007,27(14):1429-1430.
[24]许建中.沪产两红化对60例慢性疾病患者免疫调节作用的临床脱察.上海中医药杂志,1998(1):32-33.
[25]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P531-532.
[26]宋凡波,朱元元,张京玲,等.没药的研究进展.中草药,2006,37(11):附1.
[27]叶建红.对药乳香没药的药理作用与临床应用体会.安徽中医临床杂志,2003,15(3):264-265.
[28]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P552-553.
[29]冯爱成.王不留行改善血瘀模型豚鼠血液粘度实验研究.时珍国医医药,1998,9(5):432.
[30]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P177-179.
[31]吴艳玲,朴惠善.蒲公英的药理研究进展.时珍国医国药,2004,15(8):519-520.
[32]凌云,郑俊华.中药蒲公英的研究进展.中国现代应用药学杂志,1998,15(3):10-13.
[33]金政,金松竹,李相五,等.蒲公英对衰老大鼠脑组织氧自由基相关指标的影响.中国中医药科技,2002,9(2):8.
[34]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P193-194.
[35]张凤梅,李洪源,李霞,等.败酱草多糖体外抗呼吸道合胞病毒作用的研究.黑龙江医药科学,2006,29(1):48.
[36]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P54-58.
[37]张富强,聂红,韦艺,等.白芷的化学与药理研究进展.南京中医药大学学报(自然科学版),2002,18(3):190-192.
[38]聂红,沈映君.白芷挥发油对伤害性疼痛模型大鼠基因表达的影响.中药新药与临床药理,2003,14(1):21-23.
[39]聂红,沈映君,曾南,等.白芷总挥发油对疼痛模型大鼠的神经递质的影响.中药药理与临床,2002,18(3):11-14.
[40]马子密,傅延龄.历代本草药性汇解.北京版.中国医药科技出版社,2002.P461-463.
[41]王应斌,穆仙丽,宿水成.蒙药川楝子的药理作用研究概况.中国民族医药杂志,2002,8(4):54-56.
[42]贺亮,宋先亮,殷宁,等.川楝子总黄酮和多糖提取及其抗氧化活性研究.林产化学与工业,2007,27(5):78-82.
[43]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P423-424.
[44]吴金英,孙建宁.复方石韦片主要药效学实验研究.中成药,2000,22(6):428-431.
[45]吴金英,贾占红,孙建宁,等.复方石韦片主要药效的实验研究.浙江实用医学,2005,10(5):311-313.
[46]朱燕飞.枸杞子药理作用概述.浙江中西医结合杂志,2005,15(5):322-323.
[47]钱彦丛,宇文萍.枸杞子的化学成分及药理研究新进展.中医药学报,2000,28(4):34.
[1]吴阶平.吴阶平泌尿外科学.济南:山东科学技术出版社,2004.P579-586.
[2]那彦群.中国泌尿外科疾病诊断治疗指南.北京:人民卫生出版社,2007.P219-225.
[3]郑筱萸.中药新药临床研究指导原则.北京:中国医药科技出版社,2002.P168-172.
[4]吴阶平.吴阶平泌尿外科学.济南:山东科学技术出版社,2004.P1989.
[5]徐福松,陈乃光.慢性前列腺炎诊断疗效标准.成都:中华中医药学会男科学会第三届学术研讨会论文汇编,1998.P179-181.
[6]王琦.王琦男科学.郑州:河南科学技术出版社,2007.P645-646.
[7]郑筱萸.中药新药临床研究指导原则.北京:中国医药科技出版社,2002.P168-169.
[8]李兰群,王传航,刘春英.慢性前列腺炎中医证型分布频率研究.中华中医药杂志,2005,20(4):245-246.
[9]张亚强,胡镜清.慢性前列腺炎中药新药临床试验中的若干问题的探讨.中药新药与临床药理,2007,18(6):489.
[10]Litwin MS.A review of the development and validation of the National Institutes Health Chronic prostatitis symptom Index.J Urol,2002,60(6 Suppl):14-18.
[11]张亚强.活血化瘀是治疗慢性前列腺炎的有效治则和方法.中国中西医结合杂志,2002,22(3):218.
[12]Tsuboi N,Nishimura T,Chen H,et al.Relation of leukocytosis in prostatic fluid and inflamed prostatic tissue.J Nippon Med Sch,2007,74(3):210-216.
[13]李宏军,商学军,黄宇烽.IL-10、IL-8在慢性前列腺炎中的改变及意义.中华男科学杂志,2004,10(7):486-488.
[14]夏国守,何映,缪界平,等.前列腺按摩液IL-8测定在Ⅲ型前列腺炎分型中的临床意义.中国男科学杂志,2007,21(8):41-43.
[15]王瑞,郑涛,王祖龙.不同症状慢性前列腺炎患者前列腺按摩液pH值、卵磷脂小体与白细胞数比较.郑州大学学报(医学版),2006,41(5):947-948.
[16]王瑞,张卫星,郑涛,等.前列腺按摩液pH测定在慢性前列腺炎中的临床应用价值.中华男科学杂志,2004,10(8):630-631.
[17]郝宗耀,梁朝朝,张学军,等.慢性前列腺炎忠肯前列腺液、尿液电解质测定及其相关性研究.中华泌尿外科杂志,2004,25(7):465-468.
[1]Chemyshov VP.Lymphocyte response to phytomitogens in comparison to autoimmune reactions and the state of spermatogenesis in uro(urethro)genic experimental prostatitis in dogs.Fiziol Zh,1979,25(3):286-296.
[2]Robinette CL.Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate.Prostate,1988,12(3):271-286.
[3]Casas-Ingaramo A,Depiante-Depaoli M,Pacheco-Rupil B.Activation ofcytotoxic cells by syngeneic prostate antigens in experimental autoimmune vesiculo-prostatitis.Autoimmunity,1991,9(2):151-157.
[4]Keetch DW,Humphrey P,Ratliff TL.Development of a mouse model for nonbacterial prostatitis.J Urol,1994,152(1):247.
[5]Maccioni M,Rivero VE,Riera CM.Prostatein(or rat prostatic steroid binding protein) is a major autoantigen in experimental autoimmune prostatitis.Clin Exp Immunol,1998,112(2):159-165.
[6]Rivero V,Camaud C,Riera CM.Prostatein or steroid binding protein(PSBP) induces experimental autoimmune prostatitis(EAP) in NOD mice.Clin Immunol,2002,105(2):176-184.
[7]Penna G,Amuchastegui S,Cossetti C,et al.Spontaneous and prostatic steroid binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic mouse.J Immunol,2007,179(3):1559-1567.
[8]叶伟成,薛慈民,徐兆东,等.免疫佐剂法制作慢性非细菌性前列腺炎小鼠模型的方法.中国男科学杂志,2001,15(1):29.
[9]周晓辉,韩蕾,周智恒,等.免疫性慢性非细菌性前列腺炎大鼠模型的形态学与分子生物学特性.中国男科学杂志,2005,11(4):290.
[10]魏武然,张唯力,戴君永.大鼠模型非细菌性前列腺炎模型的建立.中国男科学杂志,2006,20(1):22-24.
[1]何诚.实验动物学.北京:中国农业大学出版社,2006.P283.
[2]Honda H,Miharu N,Ohashi Y,et al.Fetal gender determination in early pregnancy through qualitative and quantitative analysis of fetal DNA in maternal serum.Hum Genet,2002,110(1):75-79.
[3]Pontari MA,Ruggieri MR.Mechanisms in prostatitis/chronic pelvic pain syndrome.J Urol,2004,172(3):839-845.
[4]Ponniah S,Arah I,Alexander RB.PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome.Prostate,2000,44(1):49-54.
[5]Keith IM,Jin J,Neal D Jr,et al.Cell relationship in a Wistar rat model of spontaneous prostatitis.J Urol,2001,166(1):323-328.
[1]郭应禄,李宏军.前列腺炎.北京:人民军医出版社,2007.P346.
[2]Jang TL,Schaeffer AJ.The role of cytokines in prostatitis.World J Urol,2003,21(2):95-99.
[3]鲍国强,章扬培.NF-κB的生物学功能.国外医学分子生物学分册,2003,25(6):345-348.
[4]李永春.核因子-κB与炎症性疾病.国外医学内科学分册,2000,27(11):488-491.
[5]张亚强,刘猷枋.前列腺方治疗慢性前列腺炎血瘀证的临床与实验研究.中国中西医结合杂志,1998,18(9):534-536.
[6]张亚强,卢建新,吴志奎,等.丹蒲胶囊对慢性前列腺炎患者前列腺液IL-2、IL-6水平的影响.中国中西医结合杂志,2002,22(11):828-829.
[7]段志国,杨为民.细胞因子与慢性前列腺炎关系的研究现状.中国男科学杂志,2005,19(1):57-59.
[8]郑国光.核因子-κB与炎症和肿瘤.白血病淋巴瘤,2005,14(5):290-295.
[9]Dinarello CA.Proinflammatory cytokines.Chest,2000,118(2):503-508.
[10]Nadler RB,Koch AE,Calhoun EA,et al.IL-lbeta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis.J Urol,2000,164(1):214-218.
[11]Alexander RB,Ponniah S,Hasday J,et al.Elevated levels ofproinflammatory cytokines in the semen of patients with Chronic prostatitis/chronic pelvic pain syndrome.Urology,1998,52(5):744-749.
[12]Yang J,Ye L,Jiang H,et al.Clinical evaluation of IL-lbeta and TNF-alpha in prostatic secretions for chronic prostatitis.Zhonghua Nan Ke Xue,2004,10(6):449-454.
[13]Hochreiter WW,Nadler RB,Koch AE,et al.Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions.J Urol,2005,174(2):589.
[14]Penna G,Mondaini N,Amuchastegui S,et al.Seminal plasma cytokines and chemokines in prostate inflammation:interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.Eur Urol,2007,51(2):524-533.
[15]李宏军,商学军,黄宇烽.IL-10、IL-8在慢性前列腺炎中的改变及意义.中华男科学杂志,2004,10(7):486-487.
[16]Miller LJ,Fischer KA,Goralnick SJ,et al.Intedeukin-10 levels in seminal plasma:implications for chronic prostatitis/chronic pelvic pain syndrome.J Urol,2002,167(2 Pt 1):753-756.
[17]李树平,孟双艳,李锐.血清和前列腺液中四种细胞因子水平与慢性非细菌性前列腺炎的关系.中国医师杂志,2005,7(11):1444-1446.
[1]郭应禄,李宏军.前列腺炎.北京:人民军医出版社,2007.P92.
[2]Miller LJ,Fischer KA,Goralnick SJ,et al.Nerve Growth factor and chronic prostatitis/chronic pelvic Pain syndrome.Urology,2002,59(4):603-608.
[3]Shahed AR,Shoskes DA.Correlation of endorphin and prostaglandin E2 Levels in prostatic fluid of patients with chronic prostatitis with diagnosis and trentment.J Urol,2001,166(5):1738-1741.
[4]陈勇,宋波,熊恩庆,等.慢性前列腺炎疼痛产生的神经机制的实验研究.第三军医大学学报,2003,25(15):1358-1360.
[5]张亚强,刘猷枋.前列腺方治疗慢性前列腺炎血瘀证的临床与实验研究.中国中西医结合杂志,1998,18(9):534-535.
[6]高英茂.组织学与胚胎学.北京:人民卫生出版社,2001.P107.
[7]陈曦,李凡.Glucosamine Chondroitin与黄芩联合对佐剂性关节炎大鼠血清PGE2影响的实验研究.中国实验诊断学,2005,9(1):15-17.
[8]Shahed AR,Shoskes DA.Correlation of endorphin and prostaglandin E2 Levels in prostatic fluid of patients with chronic prostatitis with diagnosis and trentment.J Urol,2001,166(5):1738-1741.
[1]郭应禄,李宏军.前列腺炎.北京:人民军医出版社,2007.P91-92.
[2]周晓辉,周智恒,刘忠德.自身免疫因素导致慢性非细菌性前列腺炎的研究进展.中国中西医结合外科杂志,2003,9(3):240-242.
[3]鲍国强,章扬培.NF-κB的生物学功能.国外医学分子生物学分册,2003,25(6):345-348.
[4]李永春.核因子-κB与炎症性疾病.国外医学·内科学分册,2000,27(11):488-491.
[5]郑国光.核因子-κB与炎症和肿瘤.白血病淋巴瘤,2005,14(5):290-295.
[6]陈勇,宋波,熊恩庆,等.慢性前列腺炎疼痛产生的神经机制的实验研究.第三军医大学学报,2003,25(15):1358-1360.
[7]高英茂.组织学与胚胎学.北京:人民卫生出版社,2001.P107.
[8]Lowe EM,Anand P,Terenghi G,et al.Increased nerve growth Factor Levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis.J Urol,1997,79(4):572-577.
[9]Gonzalez RR,Fong T,Belmar N,et al.Modulating bladder neuro-inflammation:RDP58,a novel anti-inflammatory peptide,decreases inflammation and nerve growth factor production in experimental cystitis.J Urol,2005,173(2):630-634.
[10]Miller LJ,Fischer KA,Goralnick SJ,et al.Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome.Urology,2002,59(4):603-608.
[2]李曰庆.前列腺疾病临床荟萃.北京:华夏出版社,1996.P7-8.
[3]王劲松,徐福松.再论精室当为奇恒之腑.辽宁中医杂志,2002,29(10):590.
[4]李德新.中医基础理论.北京:人民卫生出版社,2001.P93.
[5]张家锡.中医学基础.上海:上海科学技术出版社,2001.P54.
[6]吴丽丽,严灿,王文竹.中医脏腑功能与生殖.甘肃中医,2004,17(4):4-6.
[7]姜志戎.精室当属男子奇恒之腑刍议.吉林中医药,2003,23(2):5.
[8]李益生.论男性奇恒之腑.中国中医基础医学杂志,2002,8(4):19-21.
[9]吴阶平.吴阶平泌尿外科学.济南:山东科学技术出版社,2004.P1989.
[10]邢国红.施汉章教授治疗慢性前列腺炎经验介绍.新中医,2004,36(5):11-12.
[11]徐福松,陈乃光.慢性前列腺炎诊断疗效标准.成都:中华中医药学会男科学会第三届学术研讨会论文汇编,1998.P179-181.
[12]王琦.王琦男科学.郑州:河南科学技术出版社,2007.P645-646.
[13]国家中医药管理局.中华人民共和国中医药行业标准·中医病证诊断疗效标准.南京:南京大学出版社,1994.P50.
[14]郑筱萸.中药新药临床研究指导原则.北京:中国医药科技山版社,2002.P168-169.
[15]李兰群,王传航,刘春英.慢性前列腺炎中医证型分布频率研究.中华中医药杂志,2005,20(4):245-246.
[16]刘步平.广州市高校男生慢性前列腺炎中医证型分布规律的调查研究.中华男科学,2007,13(9):810-814.
[17]宋竖旗.张亚强从瘀论治慢性前列腺炎的经验.中国中医基础医学杂志,2007,13(8):609-615.
[18]姚实林.王琦从络论治前列腺痛的经验.中医杂志,2007,48(2):114-115.
[19]郭小鹏,崔崎,马超.络病学说在慢性前列腺炎治疗中的运用.新疆中医药,2004,22(2):20-22.
[20]郑胜.张敏建教授从肝论治慢性前列腺炎的经验.福建中医药,2007,38(1):15-16.
[21]张敏建.慢性前列腺炎从相火论治.江苏中医药,2006,27(5):3-4.
[22]程宛钧.张敏建老师从相火论治慢性前列腺炎经验.福建中医学院学报,2006,16(2):62-64.
[23]吕生辉,李湛民.从三焦论治前列腺炎.山西中医学院学报,2006,7(1):15-16.
[24]张春和.“诸痛痒疮,皆属于心”理论在治疗男科病中的应用举隅.云南中医学院学报,2006,29(2):35-36.
[25]白遵光,陈志强,王树声,等.从内痈论治慢性非细菌性前列腺炎/慢性盆腔疼痂综合征的临床观察.中国男科学杂志,2006,20(3):55-57.
[26]张迎春.从脾胃论治无菌性前列腺炎.中国中医药信息杂志,2006,13(6):88.
[27]何映.以”风胜湿”理论论治慢性前列腺炎.江苏中医药,2006,27(5):4-5.
[28]梁沛华,崔建锋,邓宾,等.从经筋论治Ⅲ型前列腺炎的临床研究.广州中医药大学学报,2005,22(5):348-351.
[29]付伟.试述奇经理论与男科实践.中国中医基础医学杂志,2001,7(5):13-14.
[30]李波,江立军.疏润任脉法治疗非细菌性前列腺炎临床观察.中国中西医结合杂志,2003,23(1):70-71.
[31]冯子驹.从肝论治慢性非细菌性前列腺炎128例.新中医,2007,39(7):67-68.
[32]王润林,梁生旺.慢性前列腺炎的中医分型和综合治疗.光明中医,2006,21(7):21-23.
[33]徐彩华,冷风翠,相亚杰.辨证治疗慢性前列腺炎49例.山东中医杂志,2006,25(8):535.
[34]王黎君,徐大鹏,赵继福,等.辨证治疗慢性前列腺炎683例疗效观察.中华中医药杂志,2005,20(12):757-758.
[35]邹方伟,姜兆友,霍振国.辨证施治慢性前列腺炎102例.山东中医杂志,2003,22(5):285-286.
[36]刘步平,谢建兴.红藤清前汤治疗慢性前列腺炎267例总结.湖南中医杂志,2007,23(2):26.
[37]陈磊,夏卫平,周智恒,等.红鹿合剂治疗慢性非细菌性前列腺炎的临床研究.上海中医药杂志,2006,40(4):29-30.
[38]任云峰.马鞭草冲剂治疗ⅢA型前列腺炎综合征42例.陕西中医,2005,26(8):788-789.
[39]谢坚,李慈春.加味血府逐瘀汤治疗慢性非细菌性前列腺炎80例临床观察.中国男科学杂志,2004,18(3):36-38.
[40]游峰.萆薜化浊汤治疗慢性前列腺炎34例.辽宁中医学院学报,2004,6(4):302.
[41]徐罡,鲁军,唐孝达.前列安栓治疗慢性前列腺炎:多中心双盲随机安慰剂对照试验.中华泌尿外科杂志,2002,23(5):296-298.
[42]宋严冬,王升,马忠萍.野菊花栓治疗慢性前列腺炎疗效观察.吉林中医药,2005,25(2):29.
[43]任棣.中药直肠栓治疗慢性前列腺炎82例.中国中医药信息杂志,2002,9(3):49.
[44]马杰,韩鸿雁,李尔辉.前列栓治疗慢性前列腺炎40例.中国中医急症,2002,11(6):492-493.
[45]周仕轶,王林,熊国斌.五味消毒饮加减灌肠治疗前列腺炎综合征30例疗效观察.四川中医,2006,24(6):50-51.
[46]李瑞.中药保留灌肠治疗慢性非细菌性前列腺炎48例.中医外治杂志,2006,15(6):30.
[47]莫天栩.中药灌肠及口服治疗慢性前列腺炎50例.中国中医急症,2005,14(9):839.
[48]崔飞禅,苏斌,蔡东华.中药灌肠加外敷治疗慢性非细菌性前列腺炎52例.新中医,2004,36(7):67.
[49]桂文进.中药口服与坐浴治疗非细菌性前列腺炎30例.吉林中医药,2003,23(3):19-20.
[50]徐想德.癃舒汤内服坐浴治疗慢性前列腺炎.湖北中医杂志,2002,24(7):45.
[51]曾晔,赖海标,钟亮,等.坐盆汤坐浴治疗慢性非细菌性前列腺炎的临床观察.中医外治杂志,2005,14(2):16-17.
[52]李儒文,肖萍.解毒化瘀汤配合中药离子导入法治疗慢性前列腺炎.湖北中医杂志,2006,28(8):35.
[53]汪胤.离子导人法冶疗慢性前列腺炎50例.湖北中医杂志,2004,26(2):46.
[54]何天有,赵耀东,雒成林.针刺”三阴穴”治疗慢性前列腺炎临床观察.中国针灸,2004,24(10):697-698.
[55]王铠.针灸辨证治疗慢性前列腺炎30例.四川中医,2002,20(1):72-73.
[56]初艳玲,尚艳杰.针灸治疗慢性前列腺炎31例.针灸临床杂志,2005,21(2):21-22.
[57]薛银萍,张士斌,高彤.温针灸为主治疗慢性前列腺炎疗效观察.中国针灸,2006,26(5):335-336.
[58]于漾,康井利.温针灸治疗慢性前列腺炎临床研究.辽宁中医杂志,2004,31(9):775-776.
[59]吴宏东,孙自学.芒针合前列舒丸治疗慢性前列腺炎临床观察.安徽中医学院学报,2006,25(5):21-23.
[60]杨铭.芒针治疗慢性前列腺炎68例.针灸临床杂志,2004,20(6):23.
[61]田华张,张永东,朴明武.针灸配合中药治疗慢性前列腺炎体会.中医药学刊,2006,24(5):950.
[62]宋竖旗.针药结合治疗慢性非细菌性前列腺炎56例.中医研究,2005,18(7):53-54.
[63]马久太,赵明君,卢新义.前列舒通胶囊合用喹诺酮类抗生素治疗慢性细菌性前列腺炎100例临床研究.中医杂志,2006,47(12):915-916.
[64]王万春,严张仁.中西医结合治疗慢性前列腺炎50例疗效评价.光明中医,2006,21(5):42-43.
[65]刘大伟.中西医结合治疗慢性前列腺炎150例.辽宁中医杂志,2006,33(6):716-717.
[66]罗永革,罗永新.中西医结合治疗慢性前列腺炎/慢性盆腔疼痛综合征临床观察.现代泌尿外科杂志,2006,11(2):114-115.
[67]张晓毅,周桂琴,郭英.中西医结合治疗慢性前列腺炎的疗效观察.中国中医基础医学杂志,2006,12(3):225-226.
[68]张德建,陈平,程怀瑾.中西医结合治疗慢性前列腺炎167例临床观察.中西医结合学报,2006,4(4):420-422.
[69]王和.前列腺炎.贵阳:贵州科学技术出版社,2001.P202-237.
[70]陈志强,吴清和,王树声.前列清抑菌、抗炎和改善微循环作用的实验研究.广州中医大学学报,2000,17(2):147.
[71]陆原,陈达灿,李强.中药尿路清对临床不同血清型解脉支原体及其耐药菌株的药敏实验.中华男科学,2002,8(2):512.
[72]国家中医药管理局(中华本草)编委会.中华本草.上海:上海科技出版社,1998.
[73]张敏建,褚克丹,程心玲,等.艾可合剂对小鼠抗炎镇痛作用的实验研究.中华男科学,2007,13(5):471-473.
[74]李正东,蒋学洲,夏正平.摄护宁胶囊治疗无菌性前列腺炎实验研究.中国中西医结合外科杂志,1999,5(2):46.
[75]许涛,戴宁,江安红.男炎消对大鼠实验性前列腺炎影响的病理学观察.安徽中医学报,2001,20(1):38-39.
[76]贺菊乔,朱晓明,曹晖.紫金胶囊治疗大鼠细菌性前列腺炎的实验研究.中国中医药科技,2000,7(2):72.
[77]张亚强,刘猷枋.前列腺方治疗慢性前列腺炎血瘀证的临床与实验研究.中国中西医结合杂志,1998,18(9):534-536.
[78]蒋毅,王久源.中药前必治治疗慢性前列腺炎的临床研究.中国中医基础医学杂志,1999,6(1):14.
[79]朱琦,薛慈民.慢性前列腺炎病人的尿动力学变化和治疗.中华男科学,2001,7(3):185-188.
[80]Mehik A,Hellstrom P,Lukkarinen O,etal.Increased intraprostatic pressure in patients with chronic prostatitis.Urol Res,1999,27(4):277-279.
[81]邓春华,梁宏,梅骅,等.前列腺内尿液返流在慢性前列腺炎发病中的作用.中华泌尿外科杂志,1998,19(6):288-289.
[82]张蜀武,常德贵,王久源.通关胶囊对离体人增生前列腺α1-AR的拮抗作用.中华男科学,2001,7(3):136.
[83]郝重耀.针剌“培精祛毒方”对慢性前列腺炎及前列腺痛患者尿流率的影响.针灸临床杂志,2001,17(12):13-14.
[84]慈健,刘树民,宫大鑫.前列安栓对慢性前列腺炎和良性前列腺增生症患者尿流率的影响.中国男科学杂志,2003,17(2):129-130.
[85]郭应禄,李宏军.前列腺炎.北京:人民军医出版社,2007.P92-93.
[86]周青,贺菊乔,田雪飞,等.紫金胶囊对细菌性前列腺炎模型大鼠炎性因子的影响.中国中医药信息杂志,2006,13(9):30-32.
[87]张亚强,卢建新,吴志奎,等.丹蒲胶囊对慢性前列腺炎患者前列腺液IL-2、IL-6水平的影响.中国中西医结合杂志,2002,22(11):828-829.
[88]张亚强.中药前列腺汤对实验性前列腺炎病理模型的影响.中国中西医结合杂志,1991,17(11):483-484.
[89]蒋毅,王久源.中药前必治治疗慢性前列腺炎的临床研究.中国中医基础医学杂志,1999,6(1):14-16.
[90]王瑞,张卫星,郑涛,等.前列腺按摩液pH测定在慢性前列腺炎中的临床应用价值.中华男科学,2004,10(8):630-631.
[91]徐福松,曹开镛.男科基础与临床.北京:中国科学技术出版社,1996.P58-68.
[92]林成仁,王敏,刘建勋.前列安栓在大鼠体内的药代动力学研究.中华男科学,2000,6(2):107-110.
[1]Rizzo M,Marchetti F,Travaglini F,etal.Clinical characterization of the prostatitis patient in Italy:a prospective urology outpatient study.World J Urol.2005,23(1):61-66.
[2]Mehik A,Hellstrom P,Lukkarinen O,et al.Epidemiology ofprostatitis in Finnish men:a population-based cross-sectional study.BJU Int,2000,86:443-448.
[3]Krieger JN,Riley DE,Cheah PY,et al,Epidemiology of prostatitis:new evidence for a world-wide problem,World J Urol,2003,21:70-74.
[4]郭应禄,李宏军.前列腺炎.北京:人民军医出版社.2007.P68-92.
[5]梁朝朝.慢性前列腺炎流行病学及其发病机制的研究.安徽医科大学博士学位论文.2005.P1.
[6]夏同礼,孔祥田,宓培,等.我国成人前列腺非特异性炎.中华泌尿外科志,1995,16:711-713.
[7]EV Vykhovanets,MI Resnick,GT MacLennan,et al.Experimental rodent models of prostatitis:limitations and potential.Prostate Cancer and Prostatic Diseases.2007,10(1):15-29.
[8]陈昭典.前列腺炎综合征的历史演变与进展.中国男科学杂志,2003,17(6):363.
[9]McNaughton Collins M,MacDonald R,Wilt TJ.Diagnosis and treatment of chronic abacterial prostatitis:a systematic rewiew.Ann Intern Med,2000,133(5):367-381.
[10]Riley DE,Berger RE,Miner DC,et al.Diverse and related 16SrRNA- encoding DNA sequences in prostate tissues of men with chronic prostatitis.J Clin Microbiol,1998,36(6):1646-1652.
[11]Krieger JN,Riley DE,Vessella RL,etal.Bacterial in DNA sequences in prostate tissue from patients with prostate cancer and chronic prostatitis.J Urol,2000,164(4):1221-1228.
[12]谢辉黄,慧聪,杨亦荣,等.成年人前列腺组织细菌16s rRNA基因的检测.中华医学杂志.2006,86(14):976-978.
[13]邓春华,梁宏,梅骅,等.前列腺内尿液返流在慢性前列腺炎发病中的作用.中华泌尿外科杂志,1998,19(6):288-289.
[14]Batstone GR,Doble A,Gaston JS.Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome(CPPS).Clin Exp Immunol,2002,128(2):302-307.
[15]Miller LJ,Fischer KA,Goralnick SJ,et al.Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome.Urology,2002,59(4):603-8.
[16]Nadler RB,Koch AE,Calhoun EA,etal.IL-lbeta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis.JUrol,2000,16(1):214-218.
[17]刘海红,夏欣一,吴永明,等.慢性非细菌性前列腺炎慢性骨盆疼痛综合征患者外周血TH1/TH2细胞的检测.中华男科学杂志,2006,12(4):330-332.
[18]Persson BE,Ronquist G.Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion.J Urol.1996,155(3):958-60.
[19]Kirby RS,Lowe D,Bultitude MI,et al.Intra-prostatic urinary reflux:an aetiological factor in abacterial prostatitis.Br J Urol,1982,54(6):729-31.
[20]张华江,张建龙.慢性前列腺炎患者心理状况调查.临床精神医学杂志,2006,6(6):365.
[21]李海成,阮元峰,陈联大,等.慢性前列腺炎患者心理障碍调查分析.齐齐哈尔医学院学报,2006,27(11):1283-1284.
[22]杨金瑞,刘龙飞.中国泌尿外科医师对慢性前列腺炎患者精神症状的认知及诊治行为调查.中国心理卫生杂志,2007,21(6):416.
[23]武立新,梁朝朝.慢性前列腺炎与精神障碍.中华男科学杂志,2005,11(10):780-783.
[24]Zhou JF,Xiao WQ,Zheng YC,Dong J,Zhang SM.Increased oxidative stress and oxidative damage associated with chronic bacterial prostatitis.Asian J Androl,2006,8(3):317-323.
[25]刘小平,邓岩.氧自由基在慢性前列腺炎发病中的作用.中国男科杂志,2001,15(4):254.
[26]董杰,郑一春,肖伟强,等.慢性细菌性前列腺炎与氧化应激加剧和氧化损伤的关系.中华泌尿外科杂志,2006,27(增刊2):69-73.
[27]周占松,宋波,卢根生,等.前列腺炎性疼痛与脊髓星形胶质细胞活化关系的研究.第三军医大学学报,2005,27(18):1853-1854.
[28]陈勇,宋波,熊恩庆,等.前列腺与会阴盆底联系的电刺激研究.中华泌尿外科杂志,2004,25(2):124-126.
[29]Shahed AR,Shoskes DA.Correlation of beta-endorphin and prostaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response.J Urol,2001,166(5):1738-1741.
[30]周占松,宋波,卢根生,等.慢性前列腺炎牵涉痛神经机制及其与膀胱、盆底肌的关系.解放军医学杂志,2005,30(12):1055-1057.
[31]Riley DE,Krieger JN.X Chromosomal short tandem repeat polymorphisms near the phosphoglycerate kinase gene in men with chronic prostatitis.BiochimBiophys Acta,2002,1586:99-107
[32]周任远,张燕宾.不同类型慢性前列腺炎前列腺液锌含量的分布及意义.临床泌尿外科杂志,2004,19(3):168-169.
[33]Drach GW,Fair WR,Meares EM,Stamey TA.Classification of benign diseases associated with prostatic pain:prostatitis or prostatodynia?J Urol.1978,120:266.
[34]Schaeffer AJ,Knauss JS,Landis JR,et al.Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis:the National Institutes of Health Chronic Prostatitis Cohort Study.J Urol,2002,168(3):1048-1053.
[35]吴阶平.吴阶平泌尿外科学.济南:山尔科学技术出版社,2004.P389-390.
[36]Krieger JN,Ross SO,Deutsch LA,et al.Counting leukocytes in expressed prostatic secretions from patients with chronic prostatitis/chronic pelvic pain syndrome.Urology,2003,62(1):30-34.
[37]Nickel JC.Prostatitis and related conditions.In:Walsh PC.Eds.Compbell's Urology.8 th ed.Philadelphia:Saunders.2002,603-630.
[38]Seiler D,Zbinden R,Hauri D,et al.Four-glass or two glass test for chronic prostatitis.Urologe A,2003,42(2):238-242.
[39]那彦群.中国泌尿外科疾病诊断治疗指南.北京:人民卫生出版社,2007.P223-225.
[40]Nadler RB,Collins MM,Propert KJ,et al.Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome.Urology,2006,67(2):337-342.
[41]刘猷枋,张亚强.中西医结合泌尿外科学.北京:人民卫生出版社,2007.P246
[42]Propert KJ,McNaughton-Collins M,Leiby BE,et al.A prospective study of symptoms and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome:the National Institutes of Health Chronic Prostatitis Cohort study.J Urol,2006,175(2):619-623.
[43]Cheah PY,Liong ML,Yuen KH,et al.Reliability and validity of the National Institutes of Health:Chronic Prostatitis Symptom Index in a Malaysian population.World J Urol,2006,24(1):79-87.
[44]吴阶平.吴阶平泌尿外科学.济南:山东科学技术出版社,2004.P584-586.
[45]Bundrick W,Heron SP,Ray P,et al.Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis:a randomized double-blind multicenter study.J.Urology,2003,62(3):537-541.
[46]Skerk V,Marekovic I,Markovinovic L,et al.Comparative randomized pilot study of azithromycin and doxycycline efficacy and tolerability in the treatment of prostate infection caused by Ureaplasma urealyticum.Chemotherapy,2006,52(1):9-11.
[47]李昕,李宁忱,丁强,等.α1肾上腺素能受体阻滞剂荼哌地尔治疗慢性非细菌性前列腺炎的临床研究.中华男科学杂志,2006,12(3):234-236.
[48]Mehik A,Alas P,Nickel JC,et al.Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome:a prospective,randomized,double-blind,placebo-controlled,pilot study.Urology,2003,62(3):425-429.
[49]Nickel JC,Narayan P,McKay J,et al.Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin:a randomized double blind trial.J Urol,2004,171(4):1594-1597.
[50]Evliyaoglu Y,Burgut R.Lower urinary tract symptoms,pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin;versus placebo.Int Urol Nephrol,2002,34(3):351-356.
[51]沈柏华,金晓东,蔡松良,等.α1受体阻滞剂联合抗生素治疗慢性前列腺炎疗效及机制.中华男科学杂志.2004,10(7):518-520.
[52]曾晓勇,叶章群,杨为民,等.塞来昔布治疗ⅢA型前列腺炎的临床评估.中华男科学杂志,2004,10(4):278-281.
[53]惠继红,单玉喜,阳东荣,等.塞来昔布对ⅢB型前列腺炎患者前列腺液中细胞因子的影响及临床评估.中国男科学杂志,2007,21(10):21.
[54]李宁忱,那彦群,郭宏骞,等.舍尼通治疗慢性非细菌性前列腺炎的临床研究.中华泌尿外科杂志,2003,24(9):635-637.
[55]Kaplan SA,Volpe MA,Te AE.A Prospective,1-Year Trial Using Saw Palmetto Versus Finasteride in the Treatment of Category Ⅲ Prostatitis-Chronic Pelvic Pain Syndrome.J Urol,2004,171(1):284-288.
[56]Elist J.Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome:a randomized,double-blind,placebo-controlled study.Urology,2006,67(1):60-63.
[57]乔博义.氟西汀协同治疗伴情绪障碍的慢性前列腺炎.中华男科学杂志,2004,10(2):145-146.
[58]蔡岳斌.曲唑酮治疗非细菌性前列腺炎的疗效观察.中国男科学杂志,2004,18(5):41-42.
[59]曾宪辉,冯俊铎,蒋东朋.α1受体阻断剂联合抗抑郁药治疗前列腺痛的效果.中华泌尿外科杂志,2005,26(5):351.
[60]Kastner C,Hochreiter W,Huidobro C,et al.Cooled transurethral microwave thermotherapy for intractable chronic prostatitis-results of a pilot study after 1 year.Urology,2004,64(6):1149-1154.
[61]Chiang PH,Chiang CP.Therapeutic effect of transurethral needle ablation in non-bacterial prostatitis:chronic pelvic pain syndrome type Ⅲa.Int J Urol,2004,11(2):97-102.
[62]杰瓦德,杨为民.生物反馈技术治疗慢性盆底疼痛综合征及慢性前列腺炎.临床泌尿外科杂志,2003,18(10):606-607.
[63]王振声,赵庆利,白强,等.慢性非细菌性前列腺炎的手术治疗(附102例报告).中华泌尿外科志,2000,21(12):746-748.
[64]武立新,梁朝朝,唐智国,等.前列腺液白细胞计数与临床症状的相关分析.中华泌尿外科杂志,2006,27(3):194196.
[65]李宏军,商学军,黄宇烽.IL-10、IL-8在慢性前列腺炎中的改变及意义.中华男科学杂志,2004,10(7):486-488.
[66]夏国守,何映,缪界平,等.前列腺按摩液IL-8测定在Ⅲ型前列腺炎分型中的临床意义.中国男科学杂志,2007,21(8):41-43.
[67]王瑞,郑涛,王祖龙.不同症状慢性前列腺炎患者前列腺按摩液pH值、卵磷脂小体与白细胞数比较.郑州大学学报(医学版),2006,41(5):947-948.
[68]王瑞,张卫星,郑涛,等.前列腺按摩液pH测定在慢性前列腺炎中的临床应用价值.中华男科学杂志,2004,10(8):630-631.
[69]郝宗耀,梁朝朝,张学军,等.慢性前列腺炎患者前列腺液、尿液电解质测定及其相关性研究.中华泌尿外科杂志,2004,25(7):465-468.
[1] Honda H, Miharu N, Ohashi Y, et al. Fetal gender determination in early pregnancy through qualitative and quantitative analysis of fetal DNA in maternal serum. Hum Genet, 2002,110(1):75-79.
[2] Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol, 2004,172(3):839-845.
[3] Lange U, Teichmann J. Ankylosing spondylitis and genitourinary infection. Eur J Med Res, 1999,4(1): 1-7.
[4] Chernyshov VP. Lymphocyte response to phytomitogens in comparison to autoimmune reactions and the state of spermatogenesis in uro(urethro)genic experimental prostatitis in dogs. Fiziol Zh, 1979,25(3):286-296.
[5] Robinette CL. Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. Prostate, 1988,12(3):271-286.
[6]魏武然,张唯力,戴君永．人鼠模型非细菌性前列腺炎模型的建立．中国男科学杂志, 2006,20(1)：22—24．
[7] Casas-Ingaramo A, Depiante-Depaoli M, Pacheco-Rupil B. Activation of cytotoxic cells by syngeneic prostate antigens in experimental autoimmune vesiculo-prostatitis. Autoimmunity, 1991,9(2): 151-157.
[8] Keetch DW, Humphrey P, Ratliff TL. Development of a mouse model for nonbacterial prostatitis. J Urol, 1994,152(1):247.
[9] Maccioni M, Rivero VE, Riera CM. Prostatein (or rat prostatic steroid binding protein) is a major autoantigen in experimental autoimmune prostatitis. Clin Exp Immunol, 1998,112(2):159-165.
[10] Rivero V, Carnaud C, Riera CM. Prostatein or steroid binding protein (PSBP) induces experimental autoimmune prostatitis (EAP) in NOD mice. Clin Immunol, 2002,105(2): 176-184.
[11] Penna G, Amuchastegui S, Cossetti C, etal. Spontaneous and prostatic steroid binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic mouse. J Immunol, 2007,179(3):1559-1567.
[12] Lang MD, Nicke IJC, Olson ME, etal. Rat model of experimentally induced abacterial Prostatitis. Prostate, 2000,45(3):201.
[13] Alexander RB, Ponniah S, Hasday J, etal. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology, 1998,52(5):744-749.
[14] John H, Barghom A, Funke G, etal. Noninflammatory chronic pelvic pain Syndrome immunological study in blood , ejaculate and prostate tissue. European Urology, 2001,39(1):72.
[15] Ponniah S, Arah I, Alexander RB. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate, 2000,44(1 ):49-54.
[16] Shoskes DA, Albakri Q, Thomas K, et al. Cytokine polymorphisms in men with chronic prostatitis/chronic pelvic pain syndrome: association with diagnosis and treatment response. J Urol,2002,168(1):331-335.
[17]Batstone GR,Doble A,Gaston JS.Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome(CPPS).Clin Exp Immunol,2002,128(2):302-307.
[18]顾方六.现代前列腺病学.北京:人民军医出版社,2003.P526.
[19]Razumov SV,Medvedev AA,Chirun NV,etal.Role of cytokines in the diagnosis of chronic prostatitis.Urologiia,2003(6):25-28.
[20]Miller LJ,Fischer KA,Goralnick SJ,et al.Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome.Urology,2002,59(4):603-608.
[21]Penna G,Mondaini N,Amuchastegui S,et al.Seminal plasma cytokines and chemokines in prostate inflammation:interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.Eur Urol,2007,51(2):524-533.
[22]Shoskes DA,Albakri Q,Thomas K,et al.Cytokine polymorphisms in men with chronic prostatitis/chronic pelvic pain syndrome:association with diagnosis and treatment response.J Urol,2002,168(1):331-335.
[23]段志国,杨为民.细胞因子与慢性前列腺炎关系的研究现状.中国男科学杂志,2005,19(1):57-59.
[24]Jang TL,Schaeffer AJ.The role ofcytokines in prostatitis.World J Urol,2003,21(2):95-99.
[25]Dinarello CA.Proinflammatory cytokines.Chest,2000,118(2):503-508.
[26]Nadler RB,Koch AE,Calhoun EA,et al.IL-lbeta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis.J Urol,2000,164(1):214-218.
[27]Alexander RB,Ponniah S,Hasday J,et al.Elevated levels of proinflammatory cytokines in the semen of patients with Chronic prostatitis/chronic pelvic pain syndrome.Urology,1998,52(5):744-749.
[28]Paulis G,Conti E,Voliani S,et al.Evaluation of the cytokines in genital secretions of patients with chronic prostatitis.Arch Ital Urol Androl,2003,75(4):179-186.
[29]John H,Maake C,Barghorn A,et al.Immunological alterations in the ejaculate of chronic prostatitis patients:clues for autoimmunity.Andrologia,2003,35(5):294-299.
[30]Hochreiter WW,Nadler RB,Koch AE,et al.Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions.J Urol,2005,174(2):589.
[31]Penna G,Mondaini N,Amuchastegui S,et al.Seminal plasma cytokines and chemokines in prostate inflammation:interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.Eur Urol,2007,51(2):524-533.
[32]Miller LJ,Fischer KA,Goralnick SJ,et al.Interleukin-10 levels in seminal plasma:implications for chronic prostatitis/chronic pelvic pain syndrome.J Urol,2002,167(2 Pt 1):753-756.
[33]John H,Maake C,Barghorn A,et al.Immunological alterations in the ejaculate of chronic prostatitis patients:clues for autoimmunity.Andrologia,2003,35(5):294-299.
[34]李宏军,商学军,黄宇烽.IL-10、IL-8在慢性前列腺炎中的改变及意义.中华男科学杂 志,2004,10(7):486-487.
[35]段志国,杨为民.前列腺炎患者前列腺液中IL-2、IL-8及IL-10的水平分析.中华男科学,2005,11(3):201-203.
[36]高英茂.组织学与胚胎学.北京:人民卫生出版社,2001.P107.
[37]Lowe EM,Anand P,Terenghi G,et al.Increased nerve growth Factor Levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis.J Urol,1997,79(4):572-577.
[38]Gonzalez RR,Fong T,Belmar N,et al.Modulating bladder neuro-inflammation:RDP58,a novel anti-inflammatory peptide,decreases inflammation and nerve growth factor production in experimental cystitis.J Urol,2005,173(2):630-634.
[39]蔡川川,杨日东,吴志华.细胞因子与前列腺炎.岭南皮肤性病科杂志,2004,11(3):309-311.
[40]Shahed AR,Shoskes DA.Correlation of β-endorphin and proslaglandinE2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response.J Urol,2001,166(5):1738-1741.
[41]郑国光.核因子κB与炎症和肿瘤.白血病·淋巴瘤,2005,14(5):290-295.
[42]李永春.核因子-κB与炎症性疾病.国外医学·内科学分册,2000,27(11):488-491.
[43]刘海红,夏欣一,吴永明,等.慢性仆细菌性前列腺炎/慢性骨盆疼痛综合征患者外周血Th1/Th2细胞的检测.中华男科学,2006,12(4):330-333.
[44]王红艳.自身免疫性疾病中TH1/TH2细胞平衡.国外医学免疫学分册,2000,23(6):348-350.
[1]Krieger JN,Riley DE,Cheah PY,et al.Epidemiology of prostatitis:new evidence for a world-wide problem.World J Urol,2003,21:70-74.
[2]EV Vykhovanets,MI Resnick,GT MacLennan,et al.Experimental rodent models of prostatitis:limitations and potential.Prostate Cancer and Prostatic Diseases,2007,10(1):15-29.
[3]Jang TL,Schaeffer AJ.The role ofcytokines in prostatitis.World J Urol,2003,21(2):95-99.
[4]吴阶平.吴阶平泌尿外科学.济南:山东科学技术出版社,2004.P583.
[5]张前,刘宁.吲哚美辛治疗慢性菲细菌性前列腺炎/慢性骨盆疼痛综合征患者疼痛的研究.中华泌尿外科杂志,2003,24(6):422.
[6]于勒渝,张秀英,毕振春,等.丹蒲胶囊对试验性慢性前列腺炎的病理学和免疫组织化学研究.中国中西医结合外科杂志,2002,8(5):365-368.
[7]卢建新,高筱松,庞然,等.丹蒲胶囊对大鼠细菌性前列腺炎病理模型的影响.中国中西医结合杂志,2003,23(3):204-206.
[8]张亚强,刘猷枋.前列腺方治疗慢性前列腺炎血瘀证的临床与实验研究.中国中西医结合杂志,1998,18(9):534-535.
[9]张亚强,卢建新,高筱松,等.丹蒲胶囊对前列腺炎组织细胞结构和DNA荧光强度的影响.中国中医药信息杂志,2003,10(8):38-39.
[10]张亚强,卢建新,吴志奎,等.丹蒲胶囊对慢性前列腺炎患者前列腺液IL-2、IL-6的影响.中国中西医结合杂志,2002,22(11):828-830.
[1]王勒渝,张秀英,毕振春,等.丹蒲胶囊对试验性慢性前列腺炎的病理学和免疫组织化学研究.中国中西医结合外科杂志,2002,8(5):365-368.
[2]卢建新,高筱松,庞然,等.丹蒲胶囊对大鼠细菌性前列腺炎病理模型的影响.中国中西医结合杂志,2003,23(3):204-206.
[3]张亚强,卢建新,高筱松,等.丹蒲胶囊对前列腺炎组织细胞结构和DNA荧光强度的影响.中国中医药信息杂志,2003,10(8):38-39.
[4]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P779-782.
[5]温薇.丹参的药理作用及临床应用.中医药信息,2007,24(4):54-55.
[6]孙吉兰,常云亭,宋海英,等.丹参的体外抑菌研究.时珍国医国药,2003,14(12):725.
[7]杨继英,郑军.丹参素的药理作用研究进展.中华临床医学杂志,2007,8(4):45-47.
[8]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P546-548.
[9]石宏志,高南南,李勇枝,等.泽兰有效部分对血小板聚集和血栓形成的影响.中草药,2003,34(10):923-926.
[10]石宏志.泽兰对血液流变学影响的研究与进展.中国临床康复,2004,8(34):7776-7777.
[11]冯英菊,谢人明,陈光娟,等.泽兰镇痛、镇静及对实验性肝再生作用研究.陕西中医,1999,20(2):86-87.
[12]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P219-222.
[13]张芳,陈彦,苏显中.赤芍提取物体外抑菌活性的研究.徐州医学院学报,2006,26(5):418-420.
[14]雷玲,胡竟一,余悦,等.赤芍的抗内毒素作用研究.中药药理与临床,2006,22(6):32-34.
[15]孙大军,祁功才,吕文伟,等.赤芍总苷对实验性血栓形成的影响及其作用机制.中国老年学杂志,2006,26(8):1080-1081.
[16]徐红梅,刘青云.赤芍总苷对大鼠血液流变学的影响.中国中医药信息杂志,2002,9(11):17-19.
[17]朴田,莫晓燕,林瑞峥.赤芍总苷提取液体外清除自由基和抗凝血活性的研究.中国药房,2007,18(9):643-646.
[18]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P540-544.
[19]林小明.桃仁化学成分和药理作用研究进展.蛇志,2007,19(2):130-132.
[20]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P544-546.
[21]金鸣,高子淳,王继峰.羟基红花黄色素A抑制PAF诱发的家兔血小板活化的研究.北京中医药大学学报,2004,27(5):32.
[22]陈志强,王万强,叶秀云,等.红花注射液对脑缺血/再灌注损伤家兔血清白细胞介素IL-8的影响.中国急救学,2005,25(2):118.
[23]杨丽华,张敏,马春,等.红花的现代研究进展.中国老年学杂志,2007,27(14):1429-1430.
[24]许建中.沪产两红化对60例慢性疾病患者免疫调节作用的临床脱察.上海中医药杂志,1998(1):32-33.
[25]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P531-532.
[26]宋凡波,朱元元,张京玲,等.没药的研究进展.中草药,2006,37(11):附1.
[27]叶建红.对药乳香没药的药理作用与临床应用体会.安徽中医临床杂志,2003,15(3):264-265.
[28]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P552-553.
[29]冯爱成.王不留行改善血瘀模型豚鼠血液粘度实验研究.时珍国医医药,1998,9(5):432.
[30]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P177-179.
[31]吴艳玲,朴惠善.蒲公英的药理研究进展.时珍国医国药,2004,15(8):519-520.
[32]凌云,郑俊华.中药蒲公英的研究进展.中国现代应用药学杂志,1998,15(3):10-13.
[33]金政,金松竹,李相五,等.蒲公英对衰老大鼠脑组织氧自由基相关指标的影响.中国中医药科技,2002,9(2):8.
[34]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P193-194.
[35]张凤梅,李洪源,李霞,等.败酱草多糖体外抗呼吸道合胞病毒作用的研究.黑龙江医药科学,2006,29(1):48.
[36]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P54-58.
[37]张富强,聂红,韦艺,等.白芷的化学与药理研究进展.南京中医药大学学报(自然科学版),2002,18(3):190-192.
[38]聂红,沈映君.白芷挥发油对伤害性疼痛模型大鼠基因表达的影响.中药新药与临床药理,2003,14(1):21-23.
[39]聂红,沈映君,曾南,等.白芷总挥发油对疼痛模型大鼠的神经递质的影响.中药药理与临床,2002,18(3):11-14.
[40]马子密,傅延龄.历代本草药性汇解.北京版.中国医药科技出版社,2002.P461-463.
[41]王应斌,穆仙丽,宿水成.蒙药川楝子的药理作用研究概况.中国民族医药杂志,2002,8(4):54-56.
[42]贺亮,宋先亮,殷宁,等.川楝子总黄酮和多糖提取及其抗氧化活性研究.林产化学与工业,2007,27(5):78-82.
[43]马子密,傅延龄.历代本草药性汇解.北京:中国医药科技出版社,2002.P423-424.
[44]吴金英,孙建宁.复方石韦片主要药效学实验研究.中成药,2000,22(6):428-431.
[45]吴金英,贾占红,孙建宁,等.复方石韦片主要药效的实验研究.浙江实用医学,2005,10(5):311-313.
[46]朱燕飞.枸杞子药理作用概述.浙江中西医结合杂志,2005,15(5):322-323.
[47]钱彦丛,宇文萍.枸杞子的化学成分及药理研究新进展.中医药学报,2000,28(4):34.
[1]吴阶平.吴阶平泌尿外科学.济南:山东科学技术出版社,2004.P579-586.
[2]那彦群.中国泌尿外科疾病诊断治疗指南.北京:人民卫生出版社,2007.P219-225.
[3]郑筱萸.中药新药临床研究指导原则.北京:中国医药科技出版社,2002.P168-172.
[4]吴阶平.吴阶平泌尿外科学.济南:山东科学技术出版社,2004.P1989.
[5]徐福松,陈乃光.慢性前列腺炎诊断疗效标准.成都:中华中医药学会男科学会第三届学术研讨会论文汇编,1998.P179-181.
[6]王琦.王琦男科学.郑州:河南科学技术出版社,2007.P645-646.
[7]郑筱萸.中药新药临床研究指导原则.北京:中国医药科技出版社,2002.P168-169.
[8]李兰群,王传航,刘春英.慢性前列腺炎中医证型分布频率研究.中华中医药杂志,2005,20(4):245-246.
[9]张亚强,胡镜清.慢性前列腺炎中药新药临床试验中的若干问题的探讨.中药新药与临床药理,2007,18(6):489.
[10]Litwin MS.A review of the development and validation of the National Institutes Health Chronic prostatitis symptom Index.J Urol,2002,60(6 Suppl):14-18.
[11]张亚强.活血化瘀是治疗慢性前列腺炎的有效治则和方法.中国中西医结合杂志,2002,22(3):218.
[12]Tsuboi N,Nishimura T,Chen H,et al.Relation of leukocytosis in prostatic fluid and inflamed prostatic tissue.J Nippon Med Sch,2007,74(3):210-216.
[13]李宏军,商学军,黄宇烽.IL-10、IL-8在慢性前列腺炎中的改变及意义.中华男科学杂志,2004,10(7):486-488.
[14]夏国守,何映,缪界平,等.前列腺按摩液IL-8测定在Ⅲ型前列腺炎分型中的临床意义.中国男科学杂志,2007,21(8):41-43.
[15]王瑞,郑涛,王祖龙.不同症状慢性前列腺炎患者前列腺按摩液pH值、卵磷脂小体与白细胞数比较.郑州大学学报(医学版),2006,41(5):947-948.
[16]王瑞,张卫星,郑涛,等.前列腺按摩液pH测定在慢性前列腺炎中的临床应用价值.中华男科学杂志,2004,10(8):630-631.
[17]郝宗耀,梁朝朝,张学军,等.慢性前列腺炎忠肯前列腺液、尿液电解质测定及其相关性研究.中华泌尿外科杂志,2004,25(7):465-468.
[1]Chemyshov VP.Lymphocyte response to phytomitogens in comparison to autoimmune reactions and the state of spermatogenesis in uro(urethro)genic experimental prostatitis in dogs.Fiziol Zh,1979,25(3):286-296.
[2]Robinette CL.Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate.Prostate,1988,12(3):271-286.
[3]Casas-Ingaramo A,Depiante-Depaoli M,Pacheco-Rupil B.Activation ofcytotoxic cells by syngeneic prostate antigens in experimental autoimmune vesiculo-prostatitis.Autoimmunity,1991,9(2):151-157.
[4]Keetch DW,Humphrey P,Ratliff TL.Development of a mouse model for nonbacterial prostatitis.J Urol,1994,152(1):247.
[5]Maccioni M,Rivero VE,Riera CM.Prostatein(or rat prostatic steroid binding protein) is a major autoantigen in experimental autoimmune prostatitis.Clin Exp Immunol,1998,112(2):159-165.
[6]Rivero V,Camaud C,Riera CM.Prostatein or steroid binding protein(PSBP) induces experimental autoimmune prostatitis(EAP) in NOD mice.Clin Immunol,2002,105(2):176-184.
[7]Penna G,Amuchastegui S,Cossetti C,et al.Spontaneous and prostatic steroid binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic mouse.J Immunol,2007,179(3):1559-1567.
[8]叶伟成,薛慈民,徐兆东,等.免疫佐剂法制作慢性非细菌性前列腺炎小鼠模型的方法.中国男科学杂志,2001,15(1):29.
[9]周晓辉,韩蕾,周智恒,等.免疫性慢性非细菌性前列腺炎大鼠模型的形态学与分子生物学特性.中国男科学杂志,2005,11(4):290.
[10]魏武然,张唯力,戴君永.大鼠模型非细菌性前列腺炎模型的建立.中国男科学杂志,2006,20(1):22-24.
[1]何诚.实验动物学.北京:中国农业大学出版社,2006.P283.
[2]Honda H,Miharu N,Ohashi Y,et al.Fetal gender determination in early pregnancy through qualitative and quantitative analysis of fetal DNA in maternal serum.Hum Genet,2002,110(1):75-79.
[3]Pontari MA,Ruggieri MR.Mechanisms in prostatitis/chronic pelvic pain syndrome.J Urol,2004,172(3):839-845.
[4]Ponniah S,Arah I,Alexander RB.PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome.Prostate,2000,44(1):49-54.
[5]Keith IM,Jin J,Neal D Jr,et al.Cell relationship in a Wistar rat model of spontaneous prostatitis.J Urol,2001,166(1):323-328.
[1]郭应禄,李宏军.前列腺炎.北京:人民军医出版社,2007.P346.
[2]Jang TL,Schaeffer AJ.The role of cytokines in prostatitis.World J Urol,2003,21(2):95-99.
[3]鲍国强,章扬培.NF-κB的生物学功能.国外医学分子生物学分册,2003,25(6):345-348.
[4]李永春.核因子-κB与炎症性疾病.国外医学内科学分册,2000,27(11):488-491.
[5]张亚强,刘猷枋.前列腺方治疗慢性前列腺炎血瘀证的临床与实验研究.中国中西医结合杂志,1998,18(9):534-536.
[6]张亚强,卢建新,吴志奎,等.丹蒲胶囊对慢性前列腺炎患者前列腺液IL-2、IL-6水平的影响.中国中西医结合杂志,2002,22(11):828-829.
[7]段志国,杨为民.细胞因子与慢性前列腺炎关系的研究现状.中国男科学杂志,2005,19(1):57-59.
[8]郑国光.核因子-κB与炎症和肿瘤.白血病淋巴瘤,2005,14(5):290-295.
[9]Dinarello CA.Proinflammatory cytokines.Chest,2000,118(2):503-508.
[10]Nadler RB,Koch AE,Calhoun EA,et al.IL-lbeta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis.J Urol,2000,164(1):214-218.
[11]Alexander RB,Ponniah S,Hasday J,et al.Elevated levels ofproinflammatory cytokines in the semen of patients with Chronic prostatitis/chronic pelvic pain syndrome.Urology,1998,52(5):744-749.
[12]Yang J,Ye L,Jiang H,et al.Clinical evaluation of IL-lbeta and TNF-alpha in prostatic secretions for chronic prostatitis.Zhonghua Nan Ke Xue,2004,10(6):449-454.
[13]Hochreiter WW,Nadler RB,Koch AE,et al.Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions.J Urol,2005,174(2):589.
[14]Penna G,Mondaini N,Amuchastegui S,et al.Seminal plasma cytokines and chemokines in prostate inflammation:interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.Eur Urol,2007,51(2):524-533.
[15]李宏军,商学军,黄宇烽.IL-10、IL-8在慢性前列腺炎中的改变及意义.中华男科学杂志,2004,10(7):486-487.
[16]Miller LJ,Fischer KA,Goralnick SJ,et al.Intedeukin-10 levels in seminal plasma:implications for chronic prostatitis/chronic pelvic pain syndrome.J Urol,2002,167(2 Pt 1):753-756.
[17]李树平,孟双艳,李锐.血清和前列腺液中四种细胞因子水平与慢性非细菌性前列腺炎的关系.中国医师杂志,2005,7(11):1444-1446.
[1]郭应禄,李宏军.前列腺炎.北京:人民军医出版社,2007.P92.
[2]Miller LJ,Fischer KA,Goralnick SJ,et al.Nerve Growth factor and chronic prostatitis/chronic pelvic Pain syndrome.Urology,2002,59(4):603-608.
[3]Shahed AR,Shoskes DA.Correlation of endorphin and prostaglandin E2 Levels in prostatic fluid of patients with chronic prostatitis with diagnosis and trentment.J Urol,2001,166(5):1738-1741.
[4]陈勇,宋波,熊恩庆,等.慢性前列腺炎疼痛产生的神经机制的实验研究.第三军医大学学报,2003,25(15):1358-1360.
[5]张亚强,刘猷枋.前列腺方治疗慢性前列腺炎血瘀证的临床与实验研究.中国中西医结合杂志,1998,18(9):534-535.
[6]高英茂.组织学与胚胎学.北京:人民卫生出版社,2001.P107.
[7]陈曦,李凡.Glucosamine Chondroitin与黄芩联合对佐剂性关节炎大鼠血清PGE2影响的实验研究.中国实验诊断学,2005,9(1):15-17.
[8]Shahed AR,Shoskes DA.Correlation of endorphin and prostaglandin E2 Levels in prostatic fluid of patients with chronic prostatitis with diagnosis and trentment.J Urol,2001,166(5):1738-1741.
[1]郭应禄,李宏军.前列腺炎.北京:人民军医出版社,2007.P91-92.
[2]周晓辉,周智恒,刘忠德.自身免疫因素导致慢性非细菌性前列腺炎的研究进展.中国中西医结合外科杂志,2003,9(3):240-242.
[3]鲍国强,章扬培.NF-κB的生物学功能.国外医学分子生物学分册,2003,25(6):345-348.
[4]李永春.核因子-κB与炎症性疾病.国外医学·内科学分册,2000,27(11):488-491.
[5]郑国光.核因子-κB与炎症和肿瘤.白血病淋巴瘤,2005,14(5):290-295.
[6]陈勇,宋波,熊恩庆,等.慢性前列腺炎疼痛产生的神经机制的实验研究.第三军医大学学报,2003,25(15):1358-1360.
[7]高英茂.组织学与胚胎学.北京:人民卫生出版社,2001.P107.
[8]Lowe EM,Anand P,Terenghi G,et al.Increased nerve growth Factor Levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis.J Urol,1997,79(4):572-577.
[9]Gonzalez RR,Fong T,Belmar N,et al.Modulating bladder neuro-inflammation:RDP58,a novel anti-inflammatory peptide,decreases inflammation and nerve growth factor production in experimental cystitis.J Urol,2005,173(2):630-634.
[10]Miller LJ,Fischer KA,Goralnick SJ,et al.Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome.Urology,2002,59(4):603-608.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |